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Abstract 
 
Interleukin-1β (IL-1β), classically considered as a pro-inflammatory cytokine, has proven 
essential to cellular defense in nearly all tissues (Kaur et al., 2014, Ren and Torres, 2009).  In 
brain, studies suggest that IL-1β has pleiotrophic effects. It acts as a neuromodulator, has been 
implicated in the pathogenic processes associated with a number of CNS diseases, but has also 
been shown to provide protection to the injured CNS.  With respect to the latter, IL-1β 
signalling appears to mitigate pathology and motor symptoms in a mouse model of 
Huntington’s disease (HD), a progressive neurodegenerative condition that targets the striatum. 
Specifically, HD mice bred onto an IL-1R1 null background demonstrate greater pathological 
striatal HTT aggregation that coincides with increased severity of motor symptoms (Wang et al., 
2010). Of interest for this thesis, mitochondrial dysfunction and subsequent reactive oxygen 
species (ROS) generation appear to precipitate neuropathology in HD (Emerit et al., 2004). Also 
of interest, is research from this laboratory demonstrating that IL-1β can protect neural cells 
against oxidant-induced injury (He et al., 2015) (Chowdhury, unpublished observations). Thus, 
in this thesis, I explored whether IL-1β signalling could protect against oxidative stress-
generated brain damage in vivo by employing a chemical model of HD.  Toward this end,  both 
male and female mice (16-18 wks) that were either null or wild-type for the IL-1β signalling 
receptor, IL-1R1, were treated systemically with 3-nitropropionic acid (3-NP), a phyto/fungal 
mitochondrial toxin (Pedraza-Chaverrí et al., 2009), for a total cumulative dose of 920mg/kg.  
Comparisons of the histological striatal injury and extent of behavioral symptomatology were 
made.  Motor symptoms —including reduced general locomotor activity, hind limb and truncal 
dystonia, and postural instability —increased progressively with increasing days of dosage with 
3-NP, in both sexes regardless of genotype, demonstrating no observable difference in 
response during treatment. Despite this, histological analysis of the striatum, measured over 
seven levels ranging from +1.22 to -0.18 from bregma, revealed that IL-1R1 null male, but not 
female, mice had a greater incidence of striatal lesions that were also larger in size compared to 
their wild-type littermate controls. These results indicate that endogenous IL-1β signalling 
mitigated 3-NP induced structural, but not functional, striatal injury in male but not female 
mice.  
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1. CHAPTER ONE 
1.1. Interleukin-1 Family of Proteins 
The interleukin-1 family consists of many cytokines and associated proteins, such as IL-
1α, IL-1β, IL-1Ra, IL-1RAcP, IL-18, IL-36Ra, IL-36α, IL-37, IL-36β, IL-36γ, IL-38, IL-33, IL-1R1, IL-
1R2, IL-18Rα, and IL-1Rrp2. The term cytokine is derived from the ancient Greek cyto, meaning 
cell and kinesis (movement). Cytokines are therefore intra-cellular signalling molecules that 
initiate a cellular response when bound to a cell surface receptor. Interleukin-1 family proteins 
have been widely studied for many years and are considered to play a key role in many 
inflammatory diseases, although recent evidence points to it having pleiotropic effects. It is not 
practical to fully detail each member of the Interleukin-1 family, therefore further discussion 
will be restricted to the proteins most relevant to this study. For an extensive review of the 
Interleukin-1 family see (Sims and Smith, 2010, Garlanda et al., 2013, Palomo et al., 2015). 
 
1.2. Discovery and Structure of IL-1β 
Inflammation is a common occurrence during infection or after physical insult and its 
role in the resolution of injury has long been the subject of medical research. Research into the 
molecular factors of inflammation by Menkin and Beeson in 1943 first identified aspects that 
could stimulate inflammation that were deemed endogenous pyrogens (Dinarello, 1984). The 
work by Menkin and Beeson was limited by the assays available at the time. A 
radioimmunoassay was developed in the 1970’s, enabling the purification of a specific pyrogen 
(Dinarello et al., 1977). Purification was achieved by using human blood samples to isolate a 
crude extract of human monocytes in vitro. Anti-serum for the pyrogens could be produced by 
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utilizing the immune system of a rabbit. Harvested antibodies could then be used in 
combination with gel filtration to separate proteins from the extract. The proteins could then 
be radio-labeled with a heavy isotope before further purification by gel filtration and ion 
exchange chromatography (Dinarello et al., 1977, Dinarello, 1984).  
The successful purification of proteins enabled more detailed studies of the 
inflammation-inducing factors. The factor that became an interest of study was named 
Interleukin-1, for the leukocytes it was derived from. Nucleotide sequencing, of both human 
and murine cDNA, was published in two studies sequentially in November and December of 
1984 (Lomedico et al., 1984, Auron et al., 1984). The two sequences only demonstrated 26% 
homology, but analysis of both associated polypeptides indicated Interleukin-1 is expressed as a 
precursor protein. A subsequent study identified two human DNA sequences, one of which had 
a high degree of similarity to the mouse sequence published in 1984 (March et al., 1985). The 
two proteins where named Interleukin1 – α (IL-1α) and Interleukin1 – β (IL-1β). IL-1α and IL-1β 
were characterized as inflammatory regulators, and have since been the focus of further study 
(Dinarello, 1988). The interleukin family of proteins have been well characterized, and 
expanded on since the discovery of IL-1α and IL-1β. 
IL-1β is the protein of interest for this study. IL-1β is synthesized in an immature form, 
which is cleaved to produce the mature ‘active’ form. IL-1β converting enzyme (ICE) is a 
cysteine protease which was found to cleave the immature form of IL-1β (Black et al., 1989). ICE 
is a homologue of the C.elegans gene CED-3 and may be referred to as caspase 1 (Wilson et al., 
1994, Martinon and Tschopp, 2007). ICE was later fully characterized and demonstrated to be 
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activated when cleaved from a larger protein, p45. ICE is solely able to produce mature IL-1β 
(Thornberry et al., 1992, Cerretti et al., 1992). 
IL-1β is a globular protein for which x-ray crystallography studies have demonstrated the 
complete structure (Priestle et al., 1988, Treharne et al., 1990). At 3Å resolution, IL-1β can be 
demonstrated to be comprised of 12 β-sheets, forming a tetrahedral tertiary structure in which 
the edges consist of anti-parallel β-sheets (Priestle et al., 1988). The core of IL-1β is stabilized by 
hydrophobic side chain interactions, resulting in a tightly packed core in a small compact 
molecule. Connecting the β-sheets are 11 domain loops, which provide some structural 
flexibility for the molecule binding site to interact with its receptor (Priestle et al., 1988). Site 
specific mutagenesis was used to identify the binding site of IL-1β for the type 1 IL-1β receptor 
(IL-1R1) in a murine model. Seven amino acids (Arg-4, Leu-6, Phe-46, Ile-56, Lys-93, Lys-103 and 
Glu-105) form a discontinuous binding site, the loss of which produces a hundred-fold loss of 
binding to IL1-R1 (Labriola-Tompkins et al., 1991). Other than the discontinuous binding site, 
the most highly conserved residues are within the core of the molecule, whereas variations are 
present in the externally facing residues and the connecting loops. The conservation of IL-1β 
across species indicates the importance of the compact core for positioning the binding 
residues, while flexibility can be maintained by interchangeable polar residues. A second 
binding site was later found (Vigers et al., 1997). Both sites interact with IL-1R1 which wraps IL-
1β with three immunoglobulin like domains. 
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1.3. Interleukin-1 Signalling Process 
IL-1β signalling is highly regulated by extended members of the Interleukin family. IL-1β 
lacks the traditional leader sequence directing secretion of the polypeptide (Dinarello, 1994). IL-
1β must be cleaved by ICE, which itself competes with antagonist pseudo-ICE (Druilhe et al., 
2001), and is transported out of the cell after ATP mediated activation of the P2X7 receptor 
(Solle et al., 2001). IL-1β signals through IL-1R1, which is expressed ubiquitously throughout 
brain tissue (Kasukawa et al., 2011). Equally, the presence of the type 2 IL-1β receptor (IL-1R2) 
further regulates signalling. IL-1R2 binds IL-1β with a ten times higher affinity than IL-1R1. 
However, the type two receptor lacks the intracellular domains required for signal transduction 
and therefore acts as a decoy (Peters et al., 2013). Interleukin 1 receptor antagonist (IL-1Ra) 
competes with IL-1β to bind IL-1R1, further suppressing signalling. IL-1β requires the accessory 
protein, IL-1RAcP, to actively signal. This provides an additional requirement and therefore 
further dependency on the cellular environment for signalling to occur (Casadio et al., 2001). 
The multiple levels of control present on IL-1β signal transduction are necessary as signal 
amplification means a small number of molecules effectively signalling can produce a significant 
cellular response. Intracellularly, IL-1R1 is in complex with MyD88, as well as IRAK and TRAF 
modifying proteins. The signal can be transduced through multiple pathways, including the 
canonical NF-κB pathway and various non-canonical MAP Kinase pathways (Rothwell and 
Luheshi, 2000). Signal transduction results in alteration of nuclear transcription and some 
evidence indicates a role in mRNA stabilization. It is to be determined the full effect and extent 
of IL-1β signalling through MAPK pathways. However, the NF-κB pathway has been extensively 
studied.  
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The NF-κB pathway is a highly involved and complicated pathway, associated with many 
different cellular processes. NF-κB was discovered in 1986 as one of three nuclear factors found 
in a study using an electrophoretic mobility shift assay to identify DNA bound proteins in the 
immune system. NF-κB was found to associate with an immunoglobulin κ enhancer, but only in 
B cells (Sen and Baltimore, 1986a). A follow up study clarified that NF-κB is present in cells that 
transcribe immunoglobulin κ light chain genes and not limited to B cells. The study was also 
able to determine that NF-κB is an inducible protein (Sen and Baltimore, 1986b). Since the 
discovery of NF-κB, associated proteins and the functional mechanism have been revealed. NF-
κB exists as either a hetero- or homodimer of any of the associated class 1 or 2 proteins except 
for RELB which is only capable of forming a heterodimer (Nabel and Verma, 1993, Gilmore, 
2006). All of the NF-κB proteins maintain a highly conserved amino terminal that contains a 
nuclear localization signal and allows for dimerization. The variation of the different 
dimerization partners enables NF-κB to act on downstream targets in a multitude of different 
cell types. In addition to the five members of the NF-κB family, there are a number of inhibitor 
proteins, called inhibitor of κB (IκB) proteins, which are activated by an IκB kinase (IKK) and an 
essential modifier, called NF-κB essential modifier (NEMO) (Perkins, 2006). NF-κB inducing 
kinase (NIK) can activate NF-κB, under appropriate circumstances independently of NEMO (Shih 
et al., 2011). The key components of NF-κB signalling have a multitude of functions that operate 
in different ways producing a large degree of variability. 
During an inflammatory event, other extracellular signalling molecules, such as 
pathogen-associated molecular patterns and danger associated molecular patterns, may in 
addition to IL-1β, stimulate NF-κB response through binding receptors (Maverakis et al., 2015, 
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Shih et al., 2011). In order for NF-κB to be activated, IκB needs to be phosphorylated by an IKK 
leading to degradation of IκB (Hayden and Ghosh, 2004), but ubiquination of IKK is needed for 
activation (Perkins, 2006). Ubiquination of NEMO occurs, which enables recruitment of IKKβ 
and IKKα to form an activation complex. The specific sites that are ubiquinated can alter this 
fate. For example, K48 linked polyubiquination can lead to protein degradation, while K63 
linked polyubiquination does not have this effect (Perkins, 2006). The activation complex is then 
able to phosphorylate IκB, signalling the protein’s degradation, and the NF-κB proteins are able 
to relocate to the nucleus (Hayden and Ghosh, 2004).  
The extent of the different NF-κB components gives an indication of the extent of the 
variation possible in NF-κB signalling. The variation and complexity of NF-κB pathway identifies 
many biological factors that may produce a cellular response after cascade activation from IL-
1β. The cellular environment may affect any one of these factors to alter or mediate the cellular 
response. Understanding of this cascade indicates the extent of the molecular web in which IL-
1β operates, demonstrating how the cellular environment can vary its response. 
 
1.4. DNA binding and potential consequences of NF-κB activation 
The different possible combinations of NF-κB class 1 and 2 proteins will alter the DNA 
binding targets once inside the nucleus. NF-κB recognises a degenerate consensus sequence, 5'-
GGGRNWYYCC-3'; in which R indicates A or G, N indicates any nucleotide, W indicates A or T, 
and Y indicates C or T (Gilmore, 2006). The degeneracy in the binding site allows the site to 
appear at a high frequency with relation to multiple genes. IL-1β activates the NF-κB pathway 
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and NF-κB promotes further expression of IL-1β (Hiscott et al., 1993, Cogswell et al., 1994). 
Such interactions between NF-κB activity and the inflammation inducing factors, like IL-1β, 
indicate the possibility of inflammation being a feedforward process. Inflammation is a 
protective function, however, it can become harmful in excess. Excessive signalling can be 
further complicated as some components of the NF-κB signalling pathway have some 
unconventional functions that can have unwanted effects. For example, IKKα has been shown 
to be capable of phosphorylating serine 10 of histone H3 in NF-κB dependent promoters 
(Espinosa et al., 2015), demonstrating that components can alter gene expression in ways other 
than direct NF-κB binding. NEMO has been found to possess unorthodox functions, specifically 
by inhibiting programmed necrosis and therefore altering finely tuned programmed cell death 
(PCD) pathways. NEMO affects a change to necrosis by binding to ubiquinated receptor 
interacting protein 1 (RIP1) to prevent RIP1 from initiating necrotic death (O'Donnell et al., 
2012). Any change to the abundance of NEMO could alter the rate and manner at which cells 
undergo PCD. Such variation in one of multiple pathways in which IL-1β can signal, indicates just 
how the single cytokine can have differing effects doth beneficial and detrimental. 
 
1.5. Pleiotropic effects of IL-1β in the Central Nervous System 
The extent of the factors controlling IL-1β signalling and the inherent complexity of the 
NF-κB pathway in which the IL-1β signal is transduced demonstrate the extent at which the 
effect of IL-1β signalling can be dependent on the cellular environment in which it is induced. In 
the central nervous system (CNS), IL-1β and IL-1R1 are expressed throughout the rodent brain 
at low basal levels and both are increased on induction of inflammation (Gayle et al., 1997, 
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French et al., 1999, Lechan et al., 1990). Classically, IL-1β has been thought of as a harmful 
factor in disease response. However, it is now clear that IL-1β can also protect CNS tissue from 
insult.  This dichotomy is exemplified by the differing contribution of IL-1β to stroke and 
Huntington’s disease.  
 
1.5.1. IL-1β and Stroke 
Cerebral ischemia or stroke occurs when blood flow to an area of the brain is blocked by a 
blood clot.  Several studies have demonstrated that IL-1β contributes to ischemic infarct in 
murine stroke models (Relton and Rothwell, 1992, Yang et al., 1998, Basu et al., 2005). 
Examination of IL-1R1 expression, following stroke, has shown upregulation in multiple brain 
regions, including the striatum (Wang et al., 1997). Such upregulation occurs in a time 
dependent manner after insult. Further in vivo experimentation has demonstrated that 
treatment with IL-1ra, the naturally occurring IL-1R1 receptor antagonist, minimizes damage 
resulting from middle cerebral artery occlusion in rat (Relton and Rothwell, 1992, Yang et al., 
1998), a result that is supported by experiments utilizing the same technique with IL-1R1 null 
mice (Fogal et al., 2007). Of import, IL-1Ra has been tested in drug trials as a possible treatment 
in stroke (Schulz et al., 1999, Lakhan et al., 2009). In a phase two medical study administering 
IL-1ra to human stroke patients, there were no adverse effects and those treated had 
significantly better health outcomes than those treated with a placebo (Emsley et al., 2005). 
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1.5.2 IL-1β in Huntington’s Disease (HD) 
HD is a condition named after George Huntington who described the condition in 1872. 
The disease was originally named Huntington’s chorea because of stereotypical movements 
associated with HD. Patients suffering with chorea had long been studied by the time George 
Huntington published, however, the identification of an hereditary chorea, only present in later 
life, predominantly contracted by males and degenerative until death was novel at the time 
(Huntington, 1872). Huntington first described the observable symptoms of the disease as 
consistent shaking and twitching, unlike the sudden debilitating fits observed in epilepsy. 
Following advances in scientific understanding, the symptoms of HD have been more explicitly 
defined. Early symptoms of HD are commonly difficult to diagnose. Initially patients will 
experience mild loss of fine motor skills, muscle stiffness and irritability (Squitieri et al., 2000). 
Early stage symptoms can be missed, but upon rapid progression consist of uncontrollable 
muscle twitch/chorea like movement, muscle rigidity, dystonia, loss of motor control, 
psychosis, obsessive-compulsive disorder, depression and anxiety (Ross and Tabrizi, 2011). 
Physical deterioration along with symptom progression in HD was described in George 
Huntington’s original characterisation and has been supported by subsequent studies. Current 
evidence indicates death typically occurs in HD patients due to respiratory failure 15-20 years 
after the onset of symptoms (Ross and Tabrizi, 2011, Walker, 2007). 
HD is defined genetically as an autosomal dominant disorder, a result of an expanded 5’-
CAG-3’ repeat in the gene, which encodes the protein Huntingtin (HTT), mapped to 
chromosome 4p16.4 (MacDonald et al., 1993). Age of onset of HD is dependent on the number 
of CAG repeats. Directly associating the severity of mutation to the severity of phenotype, the 
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higher the number of CAG repeats present in an individual’s HTT gene, the earlier in life the 
disease is likely to manifest (Ross and Tabrizi, 2011). Evidence directly linking the number of 
CAG repeats was collected by conducting linkage marker analysis on samples collected from 
150 families with large pedigrees available for testing. Findings indicated that the number of 
repeats present in a healthy individual are between 11-34 repeats whereas people who 
displayed the diseased phenotype possessed 37-86 repeats (Duyao et al., 1993). Recently, 
diagnosis and screening has increased identification of people with HD, and it has been 
determined that 36-40 repeats are likely to lead to incomplete penetrance and mild symptoms, 
while greater than 40 repeats almost always leads to development of HD (Bates et al., 2015). 
Further clarification of the predominance of HD occurrence in males is provided by genome 
analysis demonstrating a higher rate of repeat instability during spermatogenesis (Duyao et al., 
1993). Repeat instability occurs due to a phenomenon called replication slippage, which occurs 
more frequently in stretches of di- or tri-nucleotide repeats. Trinucleotide repeats, such as the 
CAG repeat seen in HD, commonly appear in eukaryotic genomes, in both coding and non-
coding regions. Replication slippage occurs due to DNA polymerase pausing during replication 
of the repeat region causing the enzyme to disassociate from the DNA strand and bind back to 
the DNA strand at a different location within the repeat region (Viguera et al., 2001). A 
replication slippage event will cause the repeat region to be lengthened or shortened 
depending on where the DNA polymerase enzyme re-joins the strand. Repeat instability in HD 
has a higher rate of occurrence in spermatogenesis with the most severe mutations occurring 
post meiosis (Yoon et al., 2003, Duyao et al., 1993, Petruska et al., 1998). 
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IL-1β levels are increased in some Huntington’s patients (Ona et al., 1999). Further, the 
inhibition of ICE delays the development of symptoms in a mouse model (Ona et al., 1999, Li et 
al., 1995). Such findings might indicate a detrimental function of IL-1β signalling in HD 
progression. However, it is important to note that ICE (aka caspase 1) is involved in the intrinsic 
apoptosis pathway (Nagata, 1997). Therefore, inhibition of ICE may result in greater survival for 
reasons not associated with IL-1β.  Research into the specific function of IL-1β in HD is still 
relatively limited and predominately focuses on the presence of mature IL-1β as a marker of 
inflammation and not on a specific function of the cytokine (Olejniczak et al., 2015). However, 
one study utilizing R-1 HD mice that were cross-bred with IL-1R1 null mice demonstrated gene-
dependent protection from IL-1R1 signalling. Using animals expressing the mutant HTT protein 
and wild type IL-1R1 as a baseline, animals heterozygous or null for IL-1R1 demonstrated 
progressively greater HTT aggregate accumulation and incrementally worse motor deficit 
(Wang et al., 2010). Such findings are consistent with IL-1 signalling being protective in HD.  
Given the spectrum of molecular events associated with IL-1β signalling, that are highly 
dependent on cellular environment, further research is clearly needed to address the function 
of IL-1β signalling in HD. 
The pathology of HD has been the focus of research for many years. At a physiological 
level HD results in distinct loss of medium spiny neurons in the dorsal region of the putamen 
and in the caudate nucleus, regions of the human brain that are referred to collectively as the 
striatum in the mouse (Vonsattel et al., 1985, Vonsattel et al., 2011). The definitive molecular 
cause of HD has yet to be fully elucidated; however there are numerous possible events that 
are associated with neuronal loss in HD. Studies utilizing a Drosophila model have shown that 
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the poly-glutamine tract, which results from the extended CAG repeats, aggregates to block 
vesicle transport along axons (Lee et al., 2004). Interruption of axonal transport starves the 
mitochondria resulting in metabolic dysfunction and axonopathy, an irreversible process in the 
CNS (Chevalier-Larsen and Holzbaur, 2006, Spencer and Schaumburg, 1977). It is reasonable to 
relate the length of the poly-glutamine tract with the rate at which HTT aggregates and 
subsequently blocks axonal transport. Neuronal loss through inhibition of axonal transport 
would fit with the data regarding the age of onset and number of CAG repeats. It is possible 
that disruption to axonal transport is only a contributory factor and other molecular 
mechanisms are in effect during HD.  
Indeed, an increase in oxidative stress have been shown to occur in human patients with 
HD. Post mortem analysis has demonstrated an increase in protein oxidation in the brain tissue 
of those affected (Sorolla et al., 2008). Similar increases in markers of oxidative stress markers 
have been identified in cell culture and animal models (Browne et al., 1999, Wyttenbach et al., 
2002). Further, greater reactive oxygen species (ROS) production has been measured in 
multiple HD mouse models, when compared to their wild type controls (Perez-Severiano et al., 
2004). Further, mitochondrial dysfunction has been associated with HD. Post mortem analysis 
of HD patients has demonstrated severe disruption of complex two and complex three of the 
electron transport chain (Tabrizi et al., 1999). Finally, study of the proteomic changes in HD 
mice has demonstrated an increase in expression of mitochondrial proteins associated with 
protection from ROS (Deschepper et al., 2012). Such findings are consistent with the generation 
of ROS and mitochondrial dysfunction being present in both human HD patients and HD 
models.   
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1.6. IL-1β and ROS 
Many neurodegenerative diseases, including HD, demonstrate are associated with an 
increase in ROS production  (Emerit et al., 2004). This could occur through disruption of the 
electron transport chain (mitochondrial damage) or inhibition of oxidative phosphorylation 
(energy deprivation) (Li et al., 2013). The ROS commonly resulting from such dysfunction is 
superoxide anion, which is rapidly converted by different forms of SOD to hydrogen peroxide, 
also a mediator of cell death (Clément et al., 1998). Hydrogen peroxide can be converted into 
highly reactive secondary free radicals in the presence of heavy metals via the Fenton reaction. 
Such free radicals result in DNA damage, lipid peroxidation and protein dysfunction (Yakes and 
Van Houten, 1997, Cabiscol et al., 2000, Ray et al., 2012). Further, the generation of ROS has 
been linked to the increase of IL-1β (Brabers and Nottet, 2006, Troy et al., 1996), and the 
presence of antioxidants, which redress a redox imbalance, have been linked with lessening IL-
1β presence (Min et al., 2003).   
Previously, we found that IL-1β enhanced the expression and functional activity of the 
cystine/glutamate transporter (system xc-) in astrocytes (Fogal et al., 2007). Interestingly, this 
transporter is vital for the uptake of cystine for the synthesis of the neuroprotective antioxidant 
molecule glutathione (GSH) (Bannai and Tateishi, 1986). This raised the intriguing possibility 
that IL-1β may upregulate processes that fundamentally protect against oxidative stress. 
Indeed, we found that interleukin-1β protected neural cells against oxidant-induced injury via 
an NFκB-dependent upregulation of GSH synthesis (He et al., 2015) (Chowdhury, unpublished 
observations). Thus, to further study the potential protective role of IL-1β in vivo, a chemical —
3-nitropropionic acid —was utilized.  3-nitropropionic acid is a naturally occurring phyto/fungal 
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mitochondrial toxin that has been shown to induce ROS and produce HD like symptoms 
associated with selective striatal lesions (Fontaine et al., 2000).  
 
1.7. 3-Nitroproprionic Acid as a Model of HD 
3-nitroprionic acid (3-NP) is a mitochondrial toxin produced by both plant species in the 
Astragalus genus and by fungi in the Aspergillus genus (Ludolph et al., 1991). It was first 
identified as a natural toxin in the legume, Indigofera endecaphylla (Morris et al., 1954). 
Multiple incidents of 3-NP poisoning, demonstrating toxicity in humans, have occurred.  
Between 1972 and 1985, 148 outbreaks of acute neurological poisoning caused by ingestion of 
moldy sugarcane were documented in China. The causative agent was 3-NP. In total, 726 
people were affected and 64 fatalities. Many more cases may have gone unreported. 
Symptoms incurred were variable and attributed to inconsistency in exposure, with children 
documented to have the most severe symptoms (He et al., 1995). Exposed individuals would 
experience headaches and nausea initially with more severely affected patients slipping into a 
coma. Those who recovered from the coma would develop dystonia between four and forty 
days after exposure. On autopsy, non-surviving patients were shown to have lesions in their 
striatum similar to that seen in HD patients (He et al., 1995). The similarity of striatal lesion and 
evident dystonia would lead to the use of 3-NP as a chemical Huntington’s model.  
Later studies demonstrated 3-NP to be an irreversible inhibitor of succinate 
dehydrogenase (SDH) (Coles et al., 1979). The enzymatic activity of SDH requires the addition of 
an FAD cofactor (Kim et al., 2012). 3-NP acts as a succinate analogue resulting in neutrophilic 
attack on the N5 super oxidized form of the flavinylated cofactor covalently bonding and 
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inactivating the active site (Alston et al., 1977, Coles et al., 1979). The inhibition of the Krebs 
cycle in neurons, but not glial cells, has been shown by labelling succinate and measuring it’s 
accumulation after administration of 3-NP (Hassel and Sonnewald, 1995). SDH, in addition to 
acting in the Krebs cycle, forms a subunit of complex 2 of the electron transport chain providing 
further opportunity for the disruption of energy disruption by 3-NP. Multiple studies have 
demonstrated a decrease in ATP after administration of 3-NP and an increase in ROS. Further, 
the administration of ROS inhibitors has been shown to attenuate damage from exposure to 3-
NP (Pedraza-Chaverrí et al., 2009, Márquez-Valadez et al., 2012). The depletion of ATP and 
increase in ROS mimics that observed in HD (Tunez et al., 2010). Despite the long history of 
study of 3-NP, its precise mode of action continues to be revealed (Francis et al., 2013).  
Nevertheless, systemic 3-NP exposure has a clearly demonstrated effect on striatal 
tissue. Lesion does occur in other regions of the brain, however the striatum remains the most 
vulnerable, being the first and most affected region. The specificity for striatum has been 
attributed to multiple factors. In the striatum there is a convergence of glutamatergic and 
dopaminergic afferents (Kötter, 1994). Energy deprivation through the disruption of oxidative 
phosphorylation results in membrane depolarization, which makes cells susceptible to 
secondary excitotoxicity (Albin and Greenamyre, 1992). Such disruption of ATP production by 3-
NP would result in greater vulnerability to extracellular glutamate. Generation of ROS can occur 
as dopamine is easily oxidized by ferric ion to produce highly reactive electron deficient 
products, such as DOPA-quinone and DA-quinone (Meiser et al., 2013). Dopamine related ROS 
products are known to inhibit glutamate vesicle transport (Berman and Hastings, 1997).  In 
turn, glutamate can inhibit the release of dopamine in the presence of hydrogen peroxide 
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(Avshalumov et al., 2003). The striatum may be further vulnerable as the endothelial cells 
constituting the blood brain barrier (BBB) of the lateral branches of the lenticulo-striate artery 
have a high density of amino acid transporters. Indeed, the administration of a glutamate 
transporter inhibitor has been shown to minimize the effect of 3-NP (Nishino et al., 2000).  
 
1.8 Project Aim 
Classically viewed as a pro-inflammatory mediator, in the brain IL-1β appears to have 
pleiotropic effects. It acts as a neuromodulator in the healthy CNS, has been implicated in the 
pathogenesis of a number of CNS diseases, and it may also provide protection to the injured 
CNS [for review see (Hewett et al., 2012)]. Of interest for this project, a recent study 
demonstrated increased Huntingtin aggregation and severity of Huntington’s disease (HD) 
symptoms in an HD mouse bred and maintained into an IL-1R1 null background (Wang et al., 
2010), demonstrating a potential protective role for IL-1β.  
Aggregates of mutant Huntingtin protein are known to affect mitochondrial dynamics 
and function (Choo et al., 2004, Chang et al., 2006), with evidence suggesting that abnormal 
mitochondrial energetics contributes to the progression of HD in both humans and in rodent 
models (Browne et al., 1999). This is further implicated by the observation that animals and 
humans exposed to the phyto/fungal mitochondrial toxin, 3-NP, exhibit neurological symptoms 
and neuropathological outcomes similar to HD patients (Ludolph et al., 1991, Sipione and 
Cattaneo, 2001, Rubinsztein, 2002). 
Abnormal energy metabolism not only leads to a decrease in cellular ATP levels, but also 
to an increase in the production of ROS (Lin and Beal, 2006). We recently demonstrated that IL-
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1β increases astrocytic glutathione production and protects these cells from oxidant injury in 
vitro (He et al., 2015). The question of whether IL-1β may provide protection in HD by 
mitigating oxidative stress, forms the basis of this study.  
This hypothesis was tested by comparing 3-NP-induced lesion, in striatal tissue, in mice 
wild-type or null for IL-1R1, the receptor for IL-1β. Oxidative stress and cell loss leading to 
impairment of motor function are generated by 3-NP through the irreversible inhibition of SDH 
(Borlongan et al., 1997a, Borlongan et al., 1997b, Borlongan et al., 1997c). 
Specific Aim: Test the consequence of loss of IL-1β signalling on behavioral and histological 
toxicity of 3-Nitroproprionic acid.   
To determine whether IL-1β is a protective molecule in the face of oxidative stress in 
vivo, we compared the extent of 3-NP injury between IL-1R1 (-/-) mice and their wild-type (+/+) 
littermates systemically treated twice per day, over a twelve-day period, with a total cumulative 
dose of 920mg/kg 3-NP. Behavioral tests assessing motor function or muscular strength were 
made daily to monitor toxicity progression. Following euthanasia, the pattern and extent of 
striatal injury was determined via histological analysis.      
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2. CHAPTER TWO 
2.1. Rationale of Pilot Study 
Early characterization of the effects of 3-NP, identified the development of striatal 
lesions and Huntington’s like symptoms (Beal, 1994, Ludolph et al., 1992, Beal et al., 1993). 
However, the use of 3-NP as a Huntington’s model demonstrated clear variability in results. 
Early work with rats produced clear strain differences and a wide variety of striatal lesions 
(Guyot et al., 1997), making it possible to categorize the animals as vulnerable or resistant. 
Vulnerability to 3-NP was associated with a rapid loss of SDH activity, whereas resistant 
animals, although experiencing the same final level of inhibition of SDH, demonstrated more 
gradual loss of activity. Such findings indicate that cell death in a 3-NP model is a cause of 
secondary factors which, when accrued in rapid succession, result in death but not as a direct 
result of SDH inhibition. Lesion size variance was also shown to be limited in a sub-acute 
paradigm as opposed to an acute paradigm (Borlongan et al., 1995, Borlongan et al., 1997c).  
In mice, both in vitro and in vivo studies have indicated a clear sex difference in the 
response to 3-NP. Male animals are predominantly vulnerable and females resistant. The sex 
difference is hormonally mediated, since in culture, cells treated with estrogen are  protected 
and those treated with testosterone incur greater injury following NP exposure, than untreated 
cells (Nishino et al., 1998). Similarly in vivo, ovariectomized females show a loss of protection, 
wherein resistance is induced in males treated with estrogen (Nishino et al., 1998, Mogami et 
al., 2008, Nishino et al., 1997). Such findings imply that estrogen is protective and testosterone 
deleterious in cases of 3-NP poisoning.  
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The use of older sexually segregated animals should minimize estrogen-mediated 
differences between male and female animals (Mogami et al., 2008). A prolonged sub-acute 
dosing paradigm, such as that described below, should minimize variation in striatal lesion, thus 
focusing experimental results on genotypic difference not hormonal or chemical. Thus, a pilot 
study was conducted on male and female animals from the C57Bl/6 inbred mouse, the 
background from which IL-1R1 null animals are created, to evaluate the effectiveness of the 
paradigm as well as to determine any sex differences.  
 
2.2. Methodology  
Animal Husbandry 
Experimental animals were purchased from the Jackson laboratory directly (JAX stock: 
000664) or bred from JAX stock in the Syracuse University animal facility. Mice were provided 
food and water ad libitum, while housed up to five animals per cage in a controlled 
temperature environment operating on a standard 12 hour light/dark cycle in our AALAC 
accredited facility. All animal procedures were conducted with IACUC approval and this 
investigator was blind to animal genotype during experimentation. 
3-Nitroproprionic Acid Dosing Protocol 
3-NP (Sigma Aldrich, N5636) was dissolved in 0.9% saline to a concentration of 25 
mg/ml, adjusted to pH 7.4 with 5M NaOH, and filter sterilized (0.2µm Nalgene). 3-NP dosing 
stock was kept at 4°C for no more than seven days. After five days of acclimatization handling, 
mice were administered 3-NP via intraperitoneal (IP) injection twice daily with an interval of 8-
12 hours using our 11 day protocol as follows: 20 mg/kg – two days, 30 mg/kg – two days, 40 
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mg/kg – two days, 50 mg/kg – two days, 60 mg/kg three days for a total cumulative dose of 920 
mg/kg, or the 12 day protocol as follows: 20 mg/kg – two days, 30 mg/kg – three days, 40 
mg/kg – three days, 50 mg/kg – three days, 60 mg/kg one day for a total cumulative dose of 
920 mg/kg.  After completion of 3-NP dosing, animals were sacrificed by cervical dislocation 
under isoflurane anaesthesia. Brains were snap frozen in O.C.T. compound (Sakura Finetek USA) 
for histological analysis. Three separate experiments were performed over two months. 
Behavioral Scoring 
Behavioral analysis was adapted from Fernagut and colleagues (Fernagut et al., 2002) 
and conducted before each injection. Hindlimb clasping, general locomotor activity, hindlimb 
dystonia, truncal dystonia and postural adjustment reflexes were assessed twice per day just 
prior to each injection by an observer blinded to genotype. The following categories were 
assessed, abnormal general behaviour, hindlimb clasping, kyphosis, hindlimb dystonia and a 
postural challenge was administered. Three scales were assigned corresponding to no 
abnormality (0), moderate (1,3) or severe deficits (2,5). Any mouse attaining a cumulative 
behavioral score ≥ 9 or sustaining a weight loss ≥ 20% was immediately sacrificed (He et al., 
2017).  
Inverted Grip 
To assess grip strength, the mouse was placed on a 1 cm square wire mesh, which was 
then inverted 180o and held 40 -50 cm over a padded surface.  The time to fall was recorded 
using a stopwatch. Each animal received up to three trials, with the longest latency to fall of the 
three trials recorded. The animal was removed from the mesh when a criterion time of 60 s was 
achieved. (Deacon, 2013).  
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Histological analysis 
Frozen brain sections (40µm) were collected serially from the rostro-caudal extent of 
each brain (+1.54 to -0.18 relative to bregma) and stained with 0.5% thionin by submersion in 
multiple wash solutions (70% EtoH, 50% EtoH, ddH2O, thionin, ddH2O, ddH2O, 70% EtoH, 95% 
EtoH, 100% EtoH, 100% EtoH, 100% Xylenes, 100% Xylenes) as previously described (He et al., 
2017). Images were captured by scanning (Epson Perfection 3170) at 2400 dpi. The lesion area, 
identified by absence of thionin staining, was quantified using NIH Image J at seven levels from 
bregma (+1.22, +1.02, +0.72, +0.52, +0.22, +0.02, and -0.18) by three individuals blind to 
genotype and experimental identification. For each level, the percent striatal damage (D) was 
calculated as a percentage of the total striatum area (T) as (D/Tx100). Area measurements were 
converted to volume using Cavalieri's principle (volume = (s1d1) + (s2d2) + (s3d3) + (s4d4) + (s5d5) + 
(s6d6) + (s7d7)), where s = lesion surface area and d = distance between two sections, as 
published (Shih et al., 2005). Data are expressed for lesion area as a percentage of striatum at 
all seven levels, and the mean lesion volume + SEM of all seven levels derived from the mean 
calculated from all three individuals. 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism, Version 7.03.  Percent data 
was transformed by the arcsin square root function (Y=arcsin[sqrt(Y/1000)], while behavioral 
score data transformed by the log10 function [Y = log (Y + 1)], prior to analysis. Comparisons of 
mass, lesion size, behavior score and grip strength were made using repeated measures two 
way analysis of variance (RM 2-way ANOVA) evaluating the main effects (Time x Sex), followed 
post-hoc by Sidak’s multiple comparison test. Lesion and morbidity incidence comparisons were 
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evaluated by Fisher’s exact test. The Kaplan–Meier survival curves, depicting the rate at which 
animals were removed, were compared by Mantel-Cox log-rank test.  
2.3. Pilot Study Results 
Animal mass was measured the morning of each day of injection. The average mass, for 
each day, shown in figure 1, was analyzed by RM 2-way ANOVA. Male and female animals 
differed significantly in mass (p=0.0001) and the mass of each significantly decreased over time 
of treatment with 3-NP (p=<0.0001). Both male and female mice demonstrated sequential mass 
loss from day seven on. Both sexes lost a similar amount of mass over the injection period (≈10-
15%). No animal from either group was removed for excessive weight loss.  
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FIGURE 1: Comparison of 3-NP-mediated mass loss in C57Bl/6J mice. Mass of male mice (n = 5) and 
females (n = 5) were assessed and recorded just prior to each 3-NP injection.  Mass was plotted as 
mean ± SEM. There was both a significant time-effect (p = <0.0001) and sex-effect (p = 0.0001), as 
determined by repeated measures two-way ANOVA.  
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Additionally, gross motor deficits, measured by twice-daily observation, were scored as 
detailed in methodology, and are shown in figure 2. Score data was transformed [Y = log (Y+1)] 
before analyzing by RM 2-way ANOVA. Both males and females development of motor deficits 
significantly over the days 3-NP was administered (p=0.0001). The right shift observed of 
female scores demonstrated a delay in the development of motor deficit. Male animals 
developed observable motor deficits from day three while females only did so from day six. The 
delay between the groups resulted in a significant difference (p=0.0087).  
 
FIGURE 2: Comparison of 3-NP-mediated motor deficit in C57Bl/6J mice. Gross motor behavior 
of male mice (n = 5) and female (n = 5) were assessed and recorded just prior to each 3-NP 
injection.  The average score for the day was plotted as mean ± SEM. There was a significant 
time-effect (p = <0.0001) and sex-effect (p = 0.0087), as determined by repeated measures two-
way ANOVA, after [Y = log (Y + 1)] transformation.  
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FIGURE 3: Comparison of lesion size and incidence between male and female C57BL/6J mice. 
Male (n = 5) and female (n = 5) were injected twice daily with 3-NP as described in methods. (A) 
Comparison of lesion area between male and female mice expressed as a percentage of total 
striatal area. No significant difference between sexes occurs at any level of bregma as determined 
by repeated measures two-way ANOVA (p = 0.8059). (B) Comparison of lesion incidence between 
male and female mice. The graph depicts the percent of mice of each sex with any size lesion 
determined by dividing the number with lesion by the total number of mice analyzed. Exact 
numbers contained within the bars. There was no significant difference in the lesion incidence as 
determined by Fisher’s exact test (p = >0.9999). 
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FIGURE 4: Comparison of the amount and rate of removal of male and female C57Bl/6J mice 
from pilot study. Mice receiving 3-NP were removed from injection series if their behavioral 
score exceeded nine (9) or if they lost >20% of their body mass. (A) A Kaplan–Meier survival curve 
depicts the rate at which the mice were removed from study. No sex differences in rate of 
removal was determined by Mantel-Cox log-rank test (p = 0.3173). (B) The day male and female 
animals were removed for sacrifice is demonstrated with each individual mouse represented by 
a data point and a line representing the median day of sacrifice. No sex differences were found 
when compared by a Mann and Whitney similarity test (p = >0.9999). 
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Quantitative analysis of the histological striatal lesion, shown in figure 3, demonstrates 
no discernible difference between male and female animals. The striatal lesion, calculated as a 
percentage of the total striatal area (fig. 3A) was not significantly different between males and 
females (p=0.8059). The degree of lesion incidence (fig. 3B) was compared by Fisher’s exact test 
which found no significant difference between the sexes (p=>0.9999). The area of lesioned 
FIGURE 5: Representative images of C57Bl/6J male and female mice. Male (n = 5) and female (n 
= 5) mice were injected twice daily with 3-NP as described in methods. Photomicrographs depict 
striatal injury in male (left) and female mice (right) at +1.02 to +0.22 from bregma at day 13 
following 3-NP exposure. Lesion identified by absence of stain within striatal area. 
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tissue was approximately 20% in both males and females but decreased to 10% at 0.22mm 
from bregma. Completion of the injection paradigm is not expected for all mice (figure 4). All 
participants had to be removed from the paradigm before study completion due to severe 
motor deficit. The rate of decline was not significantly different between males and females [fig 
4A; log rank Mantel-Cox, analysis (p=0.5127)]. The median day of animal sacrifice was day 10 
for both groups (fig. 4B). A single male and two females was removed earlier on day 9. A Mann 
and Whitney test indicated no significant difference (p=>0.9999) in median ranks between 
males and females.  
Representative images of the coronal sections analyzed for lesion area are shown in 
figure 5. Clear circular sections of the striata are seen to be absent of stain, indicating the 
absence of cellular matter. The edges of the circles are clearly defined and of approximately 
equal size in males and females. There is no sign of blood present in the lesioned area of either 
group.  
A second cohort of three male and three female mice were treated with saline vehicle. Sham 
animals received a score of one for the assessment of motor deficit for lack of activity towards 
the end of the injection paradigm, but the animals did not appear to be adversely affected. All 
completed the full injection series, and no saline treated animal developed a lesion. The female 
animals demonstrated no significant loss of mass whereas the males lost mass after day 6 of 
the paradigm. Further investigation identified a clearly different profile for loss of mass in 
response to 3-NP compared to saline in males. See supplemental data in appendix A. 
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Pilot Study Results – 12 Day Paradigm 
When utilizing the 11-day paradigm no animal was able to complete the full 11 days 
(figure 4). To determine if this could be improved on, and a higher rate of study completion 
achieved a second study was conducted to assess wild type response to the 12 day paradigm. 
Daily mass measurements in male and female mice demonstrated a clear difference in mass 
(p=<0.0001) and both groups lost mass significantly over time (p=<0.0001) when analyzed by  
FIGURE 6: Comparison of 3-NP-mediated mass loss in C57Bl/6J mice treated with 12 day 
protocol. Mass of male (n = 6) and female (n = 7) mice were assessed and recorded just prior to 
each 3-NP injection.  Mass was plotted as mean ± SEM. There was both a significant time-effect 
(p = <0.0001) and sex-effect (p = <0.0001), as determined by repeated measures two-way 
ANOVA. Black arrows indicate the day at which a male mouse was removed from the study, 
whereas blue arrows indicate the removal of a female mouse, 
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RM 2-way ANOVA (figure 6).  The males and females lost mass in a more consistent manner 
than the animals previously tested, (figure 1). Loss of mass was observed to not occur 
differently between males and females. One male (day 10) and one female (day 8) were 
removed from the paradigm early due to losing more than 20% of starting body mass. 
Assessment of gross motor deficit during the 12 day protocol (figure 7) demonstrated the same  
FIGURE 7: Comparison of 3-NP-mediated motor deficit in C57Bl/6J mice treated with 12 day 
protocol. Gross motor behavior of male (n = 6) and female (n = 7) mice were assessed and 
recorded just prior to each 3-NP injection.  The average score for the day was plotted as mean ± 
SEM. There was a significant time-effect (p = <0.0001) and there was a statistically significant 
difference between sexes (p = 0.0138), as determined by repeated measures two-way ANOVA, 
after [Y = log (Y + 1)] transformation. Black arrows indicate the day at which a male mouse was 
removed from the study, whereas blue arrows indicate the removal of a female mouse, the red 
arrow indicates the day the female mouse was found dead. 
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FIGURE 8: Comparison of fine motor deficits between male and female C57Bl/6J mice treated 
with 12 day protocol. (A) Inverted Grip: Motor strength and coordination was compared 
between male (n = 6) and female (n = 7) mice just prior to injection of 3-NP. Mice were placed on 
a wire mesh that was subsequently inverted for a maximum of 180 seconds. Each animal received 
three trials, with the longest latency to fall of the trials for each sex graphed as the mean ± SEM. 
There was a between group difference, as determined by repeated measures two-way ANOVA (p 
= 0.0006) (B) Normalized Inverted Grip: Latency to fall data was normalized as percentage of day 
0 baseline measurements, and each sex graphed as the mean ± SEM. Data was transformed by 
Y=arcsin[sqrt(Y/1000)]. There was a between group difference as determined by repeated 
measures two-way ANOVA (p = 0.0456), with statistical differences found at days 4 (p = 0.0343) 
and 8 (p = 0.0337), following post-hoc analysis.  
31 
 
M a le F e m a le
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
S E X
%
 L
E
S
IO
N
 I
N
C
ID
E
N
C
E
5 / 70 / 6
0 .7 2 0 .5 2 0 .2 2
0
5
1 0
1 5
2 0
D is t a n c e  f r o m  B r e g m a  ( m m )
S
T
R
IA
T
A
L
 L
E
S
IO
N
(%
 o
f 
to
ta
l 
s
tr
ia
tu
m
)
M a le  (n  =  6 ) F e m a le  (n  =  7 )
5 / 70 / 65 / 70 / 65 / 70 / 6
A
B
 
 
 
 
 
FIGURE 9: Comparison of lesion size and incidence between male and female C57BL/6J mice 
treated with 12 day protocol. Male (n = 6) and female (n = 7) were injected twice daily with 3-
NP as described in methods. (A) Comparison of lesion area between male and female mice 
expressed as a percentage of total striatal area. Significant differences between sex occurs at the 
three levels of bregma shown, as determined by repeated measures two-way ANOVA (p = 
0.0154), followed by Sidak’s post-hoc t-tests for multiple comparisons (p = <0.001 at all shown 
levels). (B) Comparison of lesion incidence between male and female mice. The graph depicts the 
percent of mice of each sex with any size lesion determined by dividing the number with lesion 
by the total number of mice analyzed. Exact numbers contained within the bars. There was a 
significant difference in the lesion incidence as determined by Fisher’s exact test (p = 0.021). 
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right shift seen in the original pilot study for female mice. The difference between male and 
female appears less severe in the 12 day paradigm (fig 7) as compared to the 11 day (fig 2). The 
set difference remains significant (p=0.0138). Behavior scores began to increase from day five 
and the female scores shifted to the right from the male scores after day eight. Greater 
variation is seen between individual animals, as demonstrated by the larger error bars (figure 7, 
figure 2). Two male animals and two female animals were removed for cumulative behavioral 
score, while one female was also found dead. The female was found within an hour of death 
and included in the histological analysis.  
Determination of fine motor deficit was examined by measuring skeletal muscle strength 
through timing latency to fall when a mouse is hanging upside down from a wire mesh. Baseline 
measurements taken before the start of the injection series are shown as day 0 (figure 8A). 
Subsequent measurements made on days 2,4,6,8, and 10 demonstrated an overall significant 
difference between males and females. The distinct difference seen in baseline measurement 
was removed by normalizing experimental measurements to baseline measurements (figure 
8B). Percentage data was transformed and tested by RM 2-way ANOVA, finding the significant 
difference between the groups remained (p=0.0456), post-hoc analysis demonstrated this 
difference was only present on days four and eight. In contrast to the behavioral results shown 
in figures seven to eight, in which females suffered less motor deficit, the histological analysis 
(figure 9) demonstrates that females developed larger striatal lesion than males (p=0.0154). 
Females developed lesions covering ten to fifteen percent of the striatum on average at 
0.72mm and 0.52mm from bregma. Lesion size decreased to between five and ten percent of 
the striatum at 0.22mm from bregma.  
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FIGURE 10: Assessment of C57Bl/6J lesion volume treated with 12 day protocol. Male (n = 6) 
and female (n = 7) mice were injected twice daily with 3-NP as described in methods. Lesion (A) 
and striatal (B) volume was quantified using the Cavalieri's method and graphed as the mean 
mm3 ± SEM). A one-tailed t-test with Welch’s correction revealed a significant difference 
between sexes (p = 0.0167). A significant difference was observed in striatum volume utilizing a 
two tailed test (p = 0.0007). Sample sizes differ between A and B because of removal of a 
statistically significant outlier from lesion measurements (Grub’s outlier test).  
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FIGURE 11: Comparison of the amount and rate of removal of male and female C57Bl/6J mice 
from the 12 day pilot study. Mice receiving 3-NP were removed from injection series if their 
behavioral score exceeded nine (9) or if they lost >20% of their body mass. (A) A Kaplan–Meier 
survival curve depicts the rate at which the mice were removed from study. No sex differences 
in rate of removal was determined by Mantel-Cox log-rank test (p = 0.8257). (B) The number of 
male and female mice, determined to be moribund are expressed as the percent of the total 
number of mice subjected to the systemic injection paradigm (fraction within bars). No sex 
differences were found when compared by Fisher’s exact test (p = > 0.9999).  
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In this paradigm, the males developed no distinct lesion from treatment with 3-NP. A 
single lesion was seen at one position measured of one male animal, this measurement was 
removed as an outlier, following analysis with Grubbs outlier test. Overall lesion size was 
smaller in females treated in the twelve day protocol rather than the eleven day. In the eleven 
day protocol male animal results were not significantly different from females. In the 12 day 
FIGURE 12: Representative images of C57Bl/6J male and female mice treated with 12 day 
protocol. Male (n = 5) and female (n = 5) mice were injected twice daily with 3-NP as described 
in methods. Photomicrographs of thionin stained sections depict striatal injury in female (right), 
but not male mice (left) at +1.02 to +0.22 from bregma at day 13 following 3-NP exposure. 
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protocol males, in fact, demonstrated no lesion (figure 9). Despite both paradigms 
administering the same cumulative dose, the rate of administration affects males significantly.  
Lesion incidence (figure 9B) was significantly different between males and females with 
five of seven female animals developing lesion and no male animals developing lesion 
(p=0.021). Striatal volume and lesion volume (figure 10) demonstrated that females had larger 
striatal volume than the males (p=0.0007), although the female lesion was very small (0.6mm3). 
Female lesion volume was significantly larger than male lesion volume (p=0.0337). 
The intent of changing the dosing paradigm was to improve viability of experimental 
animals. In the eleven day paradigm no animals from either group completed the program. 
Animal removal from the twelve day paradigm (figure 11) demonstrates study completion is 
improved with 50% of male animals and 45% of female animals over the injection series 
completing the study. A Kaplan-Meier survival curve (figure 11A) rate of removal, began to 
decrease from day eight and there was no significant difference between the rate of male and 
female survival (p=0.8257). 
Considering the incidence of animal removal (figure 11B), the two groups were not 
significantly different (p=>0.9999). Coronal sections of the male and female brains (figure 12) 
demonstrate the observed lesion in the female mice but no lesion is present in the males. The 
lesioned area has a distinct border and is void of stain or blemishes.  
 
2.4. Pilot Study Discussion 
To investigate the role of IL-1β signaling in a chemical HD model, 3-NP was administered 
twice daily in incremental doses. The effect of the total cumulative dose and the rate at which 
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the dose was increased on the experimental animal was unknown. It was necessary to 
determine the response to the designed dosing paradigm in the background strain of the IL-1R1 
null model before further experimentation was conducted. Sex differences in the response to 3-
NP have been reported in previous studies. It was important to investigate any possible effect 
the sex of the animal may have on the experiment. The use of animals between the age of 16 
and 18 weeks was designed to minimize any hormone mediated sex differences (Nishino et al., 
1997). 
Previous studies indicated that estrogen is the factor responsible for observed 
resistance to 3-NP in female mice (Nishino et al., 1998). In our first pilot study, using animals 
aged 16-18 weeks, both male and female animals developed lesions of a similar size and both 
groups had a similar degree of lesion incidence when treated with 3-NP in the manner detailed 
in the methodology. The histological similarity of lesion in male and female brain tissue 
indicates that any sex-mediated differences were not observable with the analysis conducted 
for this study. Previous findings had indicated that estrogen upregulates Anexin A1, leading to 
greater integrity of the blood brain barrier (BBB) (Maggioli et al., 2016). If BBB integrity was 
preserved in females, no effect on lesion size was seen in the results of this study. Gross 
behavioral deficit, as monitored through daily scoring, did demonstrate a delay in effect for 
female animals. Histological analysis demonstrated no significant difference in lesion size. The 
findings from this pilot study indicated that animal sex did not influence striatal lesion size in 
this dosing paradigm. Although no difference in histology was seen, a delay in effect may be 
present in female animals. This could be due to differences in metabolism or other 
undetermined factors.  
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In the first pilot study no animal completed the injection paradigm. Whereas, the study 
40-50% animal moribundity was expected. The need to remove all participating animals 
presented the problem of the animals receiving less than the intended total dose. In the first 
pilot study both groups of animals were removed on the same day, therefore, in this case all 
animals received approximately the same dose. Pilot study findings indicated two areas 
requiring adjustment. Ideally, striatal lesion size would be approximately 50% to facilitate the 
visualization of the benefit or detriment of removing IL-1β signalling. Secondly, study 
completion needed to be increased wherein the majority of animals could receive the full dose.  
In order to ensure relative comparability of animals with respect to total dose received, 
the injection paradigm was adjusted. Increasing striatal lesion in wild type animals to 50% is 
statistically ideal, however such severe cellular loss in the animal striatum may directly conflict 
with the priority of having sufficient animal survival. To achieve a decrease in moribundity rate, 
the increase in dose administered was changed to a more gradual escalating dose regimen. As 
3-NP irreversibly inhibits SDH any mitochondria affected would have to be replaced. Should 
viable mitochondria be able to replicate at a sufficient rate to compensate for the loss of 3-NP 
affected mitochondria, the host cell would remain viable. Extending the dosing period and 
minimizing the rate at which the doses increase may prevent the development of a feedback 
system in which cell death from 3-NP cause’s neuronal degradation. 
Having repeated the pilot study with the adjusted 12 day dosing paradigm the ability of 
the animals to complete the study was clearly improved. Further, a clear difference in male 
female histology became apparent. The intention of adjusting the dosing paradigm was to 
improve study completion, which was achieved. However, a difference in the histological 
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results between the two sexes was not expected. In male animals there is no apparent lesion 
after 12 days of treatment with 3-NP and in females lesions were present but minimal. The 
difference between the sexes in the development of motor deficit was also maintained in the 
12 day paradigm. The change in the development of motor deficit, suggests any peripheral 
effect on males and females is similar. 
The hypothesis to be tested is that the lack of IL-1β signalling will be detrimental and 
therefore increase the observed lesion area in IL-1R1 null animals. Ideally, the baseline of injury 
produced by the dosing paradigm would be sufficiently large so that both increase and 
decrease of lesion size could be observed. However, given my hypothesis, the experimental 
study continued with the 12 day paradigm as tested, because the hypothesized increase of 
lesion size would still be testable.  
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3. CHAPTER THREE 
3.1. Rationale of IL-1R1 Study 
The generation of ROS and depletion of ATP in HD as previously detailed provides a 
point of study. It is not currently known if the increase in ROS reported in HD can be attenuated 
by IL-1R1 signalling or by what mechanism this would occur. Previous research produced by this 
laboratory has demonstrated that the addition of IL-1β to astrocyte culture can protect against 
oxidant induced cell death. Further the use of IL-1R1 deficient mice to generate astrocyte 
culture negates the protection induced from IL-1β pre-treatment (He et al., 2015). These 
findings suggest that protection against ROS mediated by IL-1β, which would be experimentally 
demonstrated by an increase in striatal injury when IL-1R1 is absent. 
Additional research using murine astrocyte and neuron cultures, demonstrated that the 
organic peroxide, a ROS, tert-butyl hydroperoxide (t-BOOH) caused astrocytic and neuronal cell 
death in a concentration-dependent manner. In the presence of IL-1β, death from t-BOOH was 
attenuated, which was shown to be achieved through the upregulation of glutathione (GSH), 
the predominant antioxidant in the CNS (Chowdhury, unpublished). These results confirm 
previous studies which demonstrated IL-1β as a responsible factor for the upregulation of the 
antiporter system xc-, which plays an important role in cystine import (Fogal et al., 2007, 
Jackman et al., 2010, Shi et al., 2016). Once imported cystine is converted to cysteine the 
limiting factor in GSH production. Blocking the release of GSH from astrocytes led to loss of 
protection in neurons (Chowdhury, unpublished).   
The implementation of this study was conducted to utilize wild type and IL-1R1-/- 
animals bred from mice with a heterozygous IL-1R1 genotype in order to examine the result of 
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IL-1β signalling in the 3-NP model of HD. Building on previous in vitro work, examining the 
effect of 3-NP on the striatal tissue of animals both with and without IL-1R1 signalling will 
demonstrate if IL-1β is involved and to what extent based on the experimental conditions 
established in chapter two.  
 
3.2. Methodology 
Animal Husbandry 
Experimental animals were produced from F1 heterozygous breeding pairs bred from 
wild type (+/+) C57BL/6J females (JAX stock: 000664) and IL-1R1 null (-/-) males (JAX stock: 
003245). Resulting +/+ and -/- littermates from the F2 and F3 generations were used. 
Genotyping was conducted by standard PCR of tail DNA samples. Primers (Integrated DNA 
Technologies) 5’-GAG TTA CCC GAG GTC CAG TGG-3’ (IL-1RI WT (831)), 5’-CCG AAG AAG CTC 
ACG TTG TCA AG-3’ (IL-1RI All (832)), and 5’-GAA TGG GCT GAC CGC TTC CTC-3’ (IL-1RI KO (833)) 
identify +/+ DNA by a 1150b.p. product and -/- DNA by a 860b.p. product. Mice were provided 
food and water ad libitum, while housed up to five animals per cage in a controlled 
temperature environment operating on a standard 12 hour light/dark cycle in an AALAC 
accredited facility. All animal procedures were conducted with IACUC approval and the 
investigator was blind to animal genotype at time of experimentation. 
3-Nitroproprionic Acid Dosing Protocol 
3-NP (Sigma Aldrich, N5636) was dissolved in 0.9% saline to a concentration of 25 
mg/ml, adjusted to pH 7.4 with 5M NaOH, and filter sterilized (0.2µm Nalgene). 3-NP dosing 
stock was kept at 4°C for no more than seven days. After five days of acclimatization handling, 
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mice were administered 3-NP via intraperitoneal (IP) injection twice daily with an interval of 8-
12 hours as follows: 20 mg/kg – two days, 30 mg/kg – three days, 40 mg/kg – three days, 50 
mg/kg – three days, 60 mg/kg one day for a total cumulative dose of 920 mg/kg. Animals 
completing the protocol were sacrificed by cervical dislocation under isoflurane anaesthesia. 
Brains were snap frozen in O.C.T. compound (Sakura Finetek USA) for histological analysis. 
Three separate experiments were performed over two months. 
Behavioral Scoring 
Behavioral analysis was adapted from (Fernagut et al., 2002) and conducted before each 
injection. Hindlimb clasping, general locomotor activity, hindlimb dystonia, truncal dystonia and 
postural adjustment reflexes were assessed twice per day just prior to each injection by this 
observer blinded to genotype. Three point scales were assigned corresponding to no 
abnormality (0), moderate (1,3) or severe deficits (2,5). Any mouse attaining a cumulative 
behavioral score ≥ 9 or sustaining a weight loss ≥ 20% was immediately sacrificed (He et al., 
2017). Three separate experiments were performed over two months. 
Rotor-Rod  
Motor strength and coordination were evaluated using an automated Rotor-Rod system 
(Ugo Basile, Model 47650, with a rod diameter of 3 cm). Mice were placed on the silent 
treadmill for 15 seconds to acclimate and then the rotating treadmill set in motion with 
increasing speed up to 55 rpm over two 5 min test periods. Each animal received two trials per 
assessment, with the longest latency to fall (onto a soft surface with automatic timer), a 
measure of the ability to maintain balance, recorded per trial and then averaged. Clasping the 
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rod resulted in cessation of the trial. After a minimum of five minutes rest, a new trial was 
commenced. Two separate experiments were performed over two months. 
Inverted Grip 
To assess grip strength, the mouse was placed on a 1 cm square wire mesh, which was 
then inverted 180o and held 40 -50 cm over a padded surface.  The time to fall was recorded 
using a stopwatch. Each animal received up to three trials, with the longest latency to fall of the 
three trials recorded. The animal was removed from the mesh when a criterion time of 60 s was 
achieved. (Deacon, 2013). Two separate experiments were performed over two months 
Histological analysis 
Frozen brain sections (40µm) collected serially from the rostro-caudal extent of each 
brain (+1.54 to -0.18 relative to bregma) and stained with 0.5% thionin by submersion in 
multiple wash solutions (70% EtoH, 50% EtoH, ddH2O, thionin, ddH2O, ddH2O, 70% EtoH, 95% 
EtoH, 100% EtoH, 100% EtoH, 100% Xylenes, 100% Xylenes) as previously described (He et al., 
2017). Images were captured by scanning (Epson Perfection 3170) at 2400 dpi. The lesion area, 
identified by absence of thionin staining, was quantified using NIH Image J at seven levels from 
bregma (+1.22, +1.02, +0.72, +0.52, +0.22, +0.02, and -0.18) by three individuals blind to 
genotype and experimental identification. For each level, the percent striatal damage (D) was 
calculated as a percentage of the total striatum area (T) as (D/Tx100). Area measurements were 
converted to volume using Cavalieri's principle (volume = (s1d1) + (s2d2) + (s3d3) + (s4d4) + (s5d5) + 
(s6d6) + (s7d7)), where s = lesion surface area and d = distance between two sections, as 
published (Shih et al., 2005). Data are expressed as lesion area as a percentage of striatum at all 
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seven levels, and the mean lesion volume + SEM of all seven levels derived from the mean 
calculated from all three individuals. 
Succinate Dehydrogenase (SDH) Assay 
SDH activity was determined in crude brain mitochondrial preparations derived from 
wild type and IL-1R1 null animals. Two hours following injection with either saline or 150 mg/kg 
3-NP, brains were removed from the cranium and striatal tissue dissected and homogenized in 
an extraction buffer containing 10 mM Tris-HCl (pH 7.4), 0.44M sucrose, 10 mM EDTA and 0.1% 
BSA. Homogenates were spun (2100g, 4˚C, 5min), the supernatant collected, and re-spun 
(14,000g, 4˚C for 15min). Following aspiration of the supernatant, the crude mitochondrial 
pellet was resuspended in extraction buffer (1 ml), respun (7,000g, 4˚C for 15min) and 
resuspended again (500 µl). Twenty microliters was incubated for 20 min at 37°C in a reaction 
mixture (final volume = 200 µl) consisting of 0.1M potassium phosphate buffer (pH 7.4), 0.1M 
succinate, 0.05M sucrose, 1mg/ml p-iodonitrotetrazolium chloride (prepared fresh). The change 
in absorbance of the formazan product was read at 490 nm in a microtiter plate reader 
(Molecular Devices) (Pennington, 1961) Twenty microliters of the same crude mitochondrial 
prep was used for protein concentration measurement via the BCA assay (Thermo Scientific, 
Kalamazoo, MI). Data was normalized to the SDH activity of the saline treated animals for each 
genotype. 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism, Version 7.03.  Percent data 
was transformed by the arcsin square root function (Y=arcsin[sqrt(Y/1000)], while behavioral 
score data transformed by the function [Y = log (Y + 1)], prior to analysis. Comparisons of mass, 
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lesion size, behavior score and grip strength were made using repeated measures two way 
analysis of varience followed post-hoc by Sidak’s multiple comparison test. Lesion and 
morbidity incidence comparisons were evaluated by Fisher’s exact test. The Kaplan–Meier 
survival curves, depicting the rate at which animals were removed, were compared by Mantel-
Cox log-rank test. Differences in SDH activity was assessed by 2-way ANOVA (Treatment x 
Genotype) with Bonferroni’s multiple comparisons. 
 
3.3. IL-1R1 Results 
Male and female results are reported and considered separately due to differences 
observed in the pilot study. The results are grouped by sex. 
 
IL-1R1 Male Results 
Comparison of mass of male IL-1R1 null animals and wild type littermates (figure 13), 
demonstrated no significant difference over the course of the dosing paradigm (p=0.6635). 
Both groups differed significantly over time (p=>0.0001). Mass decreased in a steady manner. 
On average, both groups lost four grams of mass over the injection period. Two wild type, and 
three IL-1R1 null animals, were removed for losing more than 20% of body mass. The average 
mass for both groups increased on day twelve. Individual animal mass would fluctuate on a day 
to day basis with an overall downward trend. Animal removal on day eleven combined with 
small increases of mass in surviving animals could result in the increase seen in plotted 
averages. 
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Gross motor deficit (figure 14) as scored from twice daily observation demonstrated no 
significant difference between genotypes (p=0.6506). Removal for incurred motor deficit based 
on score was more common than removal for loss of mass. Five wild type and two null animals 
were removed over the injection period. In both groups motor deficit began to become 
observable from day five. Fine motor deficit (figure 15) was measured through rotor-rod testing 
for motor function and inverted grip testing for muscle strength. Wild type and IL-1R1 null  
FIGURE 13: Comparison of 3-NP-mediated mass loss in male mice. Mass of IL-1R1 null mutant 
mice (−/−, n = 12) and their wild-type littermates (+/+, n = 9) were assessed and recorded just 
prior to each 3-NP injection.  Mass was plotted as mean ± SEM. Although there was a significant 
effect over time (p = <0.0001) for both genotypes, there was no statistically significant difference 
between genotypes (p = 0.6635), as determined by repeated measures two-way ANOVA. Black 
arrows indicate the day at which a wild type animal was removed from the study, whereas blue 
arrows indicate the removal of an IL-1R1 null mutant mouse for score. 
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animals from two cohorts over two months demonstrated no significant difference in motor 
function as assessed by rotor-rod (p=0.9757). Animals from both groups demonstrated an 
increase in latency to fall from the baseline measurement until day four (figure 15A) of the 
injection paradigm, followed by a rapid decline in latency to fall by day eight. Inverted grip 
strength comparison (figure 15B) exhibited no significant difference (p=0.8986). No decrease in 
FIGURE 14: Comparison of 3-NP-mediated motor deficit in male mice. Gross motor behavior of 
IL-1R1 null mutant mice (−/−, n = 12) and their wild-type littermates (+/+, n = 9) were assessed 
and recorded just prior to each 3-NP injection.  The average score for the day was plotted as mean 
± SEM. There was a time dependent increase in behavioral deficits (p = <0.0001) that did not differ 
between genotypes (p = 0.6506) as determined by repeated measures two-way ANOVA, after 
[Y = log (Y + 1)] transformation. The black arrow indicates the day at which a wild type animal was 
removed from the study, whereas blue arrows indicate the removal of an IL-1R1 null mutant 
mouse. 
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latency to fall from the baseline measurement was observed until day four, after which both 
groups latency to fall continually declined.  
Unlike behavioral testing, histological analysis of IL-1R1 null and wild type littermate 
control animals demonstrated a significant difference (figure 16). Lesion area, as a percentage 
of striatal area (figure 16A) was significantly larger in IL-1R1 null animals (p=0.0163). The region 
from 1.02mm to 0.22mm relative to bregma contained the largest lesion. Wild type animals 
presented lesions from 0.72mm relative to bregma as opposed to IL-1R1 null animals which 
showed lesion at all measured positions. Lesion incidence (figure 16B) was more prevalent in IL-
1R1 null animals with 75% displaying lesion, compared to 37.5% of wild types, although the 
difference was not statistically significant according to a Fisher’s exact test (p=0.1675) shown in 
figure 16.  
Lesion volume was calculated from area measurements (figure 17) to examine actual 
size. Measured striatal volume was not significantly different between genotypes (Fig. 17B; 
p=0.0674). A statistically significant difference in male lesion volume, fig. 17A (p=0.01) was 
observed. Published measurements of striatal volume are shown and the relation to this study 
is discussed in Appendix A. Animal removal (figure 18) displayed the completion of the injection 
paradigm to be comparable to that shown in figure 11. The study completion of wild type and 
IL-1R1 null animals was not significantly different (p=0.2049). The incidence of animal removal 
was not significantly different between the tested groups (p=0.3964). Representative images of 
the lesions of male wild type and IL-1R1 null animals (figure 19) demonstrates a large lesion 
with blood present in the lesion of null animals and a small clear lesion for wild type. Blood was 
common in animals with larger lesions, and could indicate endothelial damage. 
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FIGURE 15: Comparison of fine motor deficits between wild type and IL-1R1 deficient male 
mice. (A) Rotor-rod: Motor strength and coordination was compared between male wild type 
(+/+, n = 8) and IL-1R1 null (-/-, n = 9) mice just prior to injection of 3-NP using an accelerated 
rotor-rod paradigm (300 sec; 5-55RPM) on the days indicated on the x axis. A record of the latency 
to fall from two independent trails was made and the data graphed as the mean ± SEM. There 
was no significant difference in time to fall between genotypes as determined by repeated 
measures two-way ANOVA (p = 0.9757). A significant time-effect was observed (p = < 0.0001). (B) 
Inverted Grip: Male wild type (+/+, n = 4) and IL-1R1 null (-/-, n = 7) were placed on a wire mesh 
that was subsequently inverted for a maximum of 180 seconds. Each animal received three trials, 
with the longest latency to fall of the trials for each genotype graphed as the mean ± SEM. There 
were no between-group differences as determined by repeated measures two-way ANOVA (p = 
0.8986). A significant time-effect was observed (p = < 0.0001). Sample sizes differ from Figure 13 
because not all cohorts received the same behavioral tests. 
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FIGURE 16: Comparison of lesion size and incidence between male wild type and IL-1R1 
deficient mice. Male IL-1R1 null mutant mice (-/-, n = 12) and their wild-type littermates (+/+, n 
= 8) were injected twice daily with 3-NP as described in methods. (A) Comparison of lesion area 
between IL-1R1+/+ and IL-1R1-/- mice expressed as a percentage of total striatal area. A significant 
difference between genotypes occurs at every level of bregma as determined by repeated 
measures two-way ANOVA (p = 0.0163), followed by Sidaks post-hoc t-tests for multiple 
comparisons (p = <0.0001 at all levels). (B) Comparison of lesion incidence between IL-1R1+/+ and 
IL1R1-/- mice. The graph depicts the percent of mice from each genotype with any size lesion 
determined by dividing the number with lesion by the total number of mice analyzed. Exact 
numbers contained within the bars. There was no significant difference in the lesion incidence 
as determined by Fisher’s exact test (p = 0.1675).  
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FIGURE 17: Assessment of male lesion volume. Male IL-1R1 null mutant mice (-/-, n = 11) and 
their wild-type littermates (+/+, n = 8) were injected twice daily with 3-NP as described in 
methods. Lesion (A) and striatal (B) volume was quantified using the Cavalieri's method and 
graphed as the mean mm3 ± SEM. A one-tailed t-test with Welch’s correction revealed a 
significant difference between genotypes (p = 0.01). No significant difference was observed in 
striatum volume utilizing a two tailed t-test (p = 0.0674). Sample sizes differ from Figure 16 
because of removal of a statistically significant outlier from the null group (Grub’s outlier test).  
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FIGURE 18: Comparison of the amount and rate of removal of wild-type (+/+) and IL-1R1 null (-
/-) male mice from 3-NP study. Mice receiving 3-NP were removed from injection series if their 
behavioral score exceeded nine (9) or if they lost >20% of their body mass. (A) A Kaplan–Meier 
survival curve depicts the rate at which the mice were removed from study. No genotypic 
differences in rate of removal was determined by Mantel-Cox log-rank test (p = 0.2049). (B) The 
number of IL-1R1+/+ and IL-1R1 −/− mice determined to be moribund are expressed as the percent 
of the total number of mice subjected to the systemic injection paradigm (fraction within bars). 
No genotypic differences were found when compared by Fisher’s exact test (p = 0.3964). 
 
53 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 IL-1R1 Females 
Like males, female animals (figure 20) demonstrat a steady continual loss of mass over 
the injection period. No significant difference between IL-1R1 null and wild type female mice 
was evident (p=0.6222). There was a significant change in mass that occurred independent of 
genotype (p=<0.0001). As demonstrated in males, mass did increase on day twelve. The 
FIGURE 19: Representative images of male wild type and IL-1R1 deficient mice. Male IL-1R1 null 
mutant mice (-/-, n = 12) and their wild-type littermates (+/+, n = 8) were injected twice daily with 
3-NP as described in methods. Photomicrographs of thionin stained sections for determination 
of striatal injury in IL-1R1+/+ (left) and IL-1R1-/- mice (right) at +0.72 to +0.22 from bregma at day 
13 following 3-NP exposure are depicted.  
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increase in average mass was likely due to the removal of animals that were most affected, and 
increases in individual animal mass.  
The gross behavior score in females (figure 21) demonstrated a significant change in 
score over time (p=<0.0001). Observable motor deficit occurred from day five, in both 
genotypes. The wild type animal score shifted to the right, indicating a delay in incurred motor 
deficit, until after day seven, but this was not statistically significant (p=0.1314). Removal of 
animals for reaching the maximum behavioral score was more prevalent in IL-1R1 null animals, 
three of which were removed. Two wild types were removed for behavioral score. Fine motor 
deficit (figure 22) was assessed by rotor-rod and inverted grip testing. No significant difference 
between genotypes was seen in rotor-rod testing over the injection series (p=0.8665). 
Additionally, significant between group difference in the latency to fall during the inverted grip 
test was seen (p=0.2813). During rotor- rod testing (figure 22A), animals demonstrated an 
increase in latency to fall from the baseline measurements up to day four of the injection series 
with loss of motor function occurring from day six to ten. 
Mice demonstrated a decrease in the latency to fall from day six to ten. Histological 
analysis of lesion area in female mice (figure 23) did not demonstrate any significant difference 
between the genotypes. Lesion area as a percentage of striatal area (figure 23A) demonstrated 
a wider spread of lesion along the striatum in female mice, but any difference was not 
statistically significant (p=0.5592). Lesion area covered 20% of striatal area in both groups, at 
the most severely lesioned positions. Lesion area in female IL-1R1 null animals was smaller than 
that of  
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female IL-1R1 null animals. Lesion incidence (figure 23B) was greater in wildtype animals but 
not statistically significant (p=0.6418). Female striatal volume was not significantly different 
between genotypes (p=0.3195). Lesion volume was not significantly different (p=0.3884). Wild 
type striatum and lesion volume are both smaller than the corresponding volume in IL-1R1 null 
animals. The lesion volume varied between 1.5 and 2.5mm3. 
FIGURE 20: Comparison of 3-NP-mediated mass loss in female mice. Mass of IL-1R1 null mutant 
mice (−/−, n = 12) and their wild-type littermates (+/+, n = 6) were assessed and recorded just 
prior to each 3-NP injection.  Mass was plotted as mean ± SEM. There was a significant time-
effect (p = <0.0001). There was no statistically significant difference between genotypes (p = 
0.6222). Determined by repeated measures two-way ANOVA. Black arrows indicate the day at 
which a wild type animal was removed from the study, whereas blue arrows indicate the removal 
of an IL-1R1 null mutant mouse. 
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The survival of female animals through the injection series (figure 25) were categorized 
as when animals completed the full injection series and “moribund” when animals met one or 
both removal conditions. The rate of study completion (figure 25A) was not significantly 
different between genotypes (p=0.5887) in females. The incidence of moribundity (figure 25B) 
was not significantly different (p=>0.9999). Representative images from female IL-1R1 null and  
FIGURE 21: Comparison of 3-NP-mediated motor deficit in female mice. Gross motor behavior 
of IL-1R1 null mutant mice (−/−, n = 12) and their wild-type littermates (+/+, n = 6) were assessed 
and recorded just prior to each 3-NP injection.  The average score for the day was plotted as 
mean ± SEM. There was a significant time-effect (p = <0.0001), but there was no statistically 
significant difference between genotypes (p = 0.1314). Determined by repeated measures two-
way ANOVA, after [Y = log (Y + 1)] transformation. Blue arrows indicate the removal of an IL-1R1 
null mutant mouse. 
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FIGURE 22: Comparison of fine motor deficits between wild type and IL-1R1 deficient female 
mice. (A) Rotor-rod: Motor strength and coordination was compared between female wild type 
(+/+, n = 5) and IL-1R1 null (-/-, n = 10) mice just prior to injection of 3-NP using an accelerated 
Rotor-rod paradigm (300 sec; 5-55RPM) on the days indicated on the x axis. A record of the 
latency to fall from two independent trials was made and the data graphed as the mean ± SEM. 
There was no significant difference in time to fall between genotypes as determined by repeated 
measures two-way ANOVA (p = 0.8665). A significant time-effect was observed (p = < 0.0001) (B) 
Inverted Grip: Female wild type (+/+, n = 3) and IL-1R1 null (-/-, n = 7) were placed on a wire mesh 
that was subsequently inverted for a maximum of 180 seconds. Each animal received three trials, 
with the longest latency to fall of the trials for each genotype graphed as the mean ± SEM. There 
were no between-group differences as determined by repeated measures two-way ANOVA (p = 
0.2813) A significant time-effect was observed (p = < 0.0001). Sample sizes differ from Figure 21 
because not all cohorts received the same behavioral tests.  
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FIGURE 23: Comparison of lesion size and incidence between female wild type and IL-1R1 
deficient mice. Female IL-1R1 null mutant mice (-/-, n = 12) and their wild-type littermates (+/+, 
n = 6) were injected twice daily with 3-NP as described in methods. (A) Comparison of lesion area 
between IL-1R1+/+ and IL1R1-/- mice expressed as a percentage of total striatal area. No significant 
difference between genotypes occurs determined by repeated measures two-way ANOVA after 
Y=arcsin[sqrt(Y/1000)] transformation (p = 0.5592). (B) Comparison of lesion incidence between 
IL-1R1+/+ and IL-1R1-/- mice. The graph depicts the percent of mice from each genotype with any 
size lesion determined by dividing the number with lesion by the total number of mice analyzed. 
Exact numbers contained within the bars. There was no significant difference in the lesion 
incidence as determined by Fisher’s exact test (p = 0.6148).  
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FIGURE 24: Assessment of female lesion volume. Female IL-1R1 null mutant mice (-/-, n = 12) 
and their wild-type littermates (+/+, n = 6) were injected twice daily with 3-NP as described in 
methods. Lesion (A) and striatal (B) volume was quantified using the Cavalieri's method and 
graphed as the mean mm3 ± SEM. A one-tailed t-test with Welch’s correction revealed no 
significant difference between genotypes (p = 0.1942). No significant difference was observed in 
striatum volume, utilizing a two tailed test (p = 0.3951).  
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wild type animals (figure 26) treated with 3-NP demonstrate similar lesion size in both 
genotypes. A tendency for larger lesion size in IL-1R1 null animals was present but this was not 
statistically significant. 
 
SDH Measurements 
Animals treated with a 150mg/kg dose of 3-NP, demonstrated a loss of SDH activity in 
the striatum, cortex and hippocampus. Of interest to this study is the effect on the striatum. 
Male, female, wild type and IL-1R1 null animal’s lost SDH activity equally in the striatum (figure 
27). Male animals demonstrated a significant loss in SDH activity when treated with 3-NP, 
normalized to saline injection, regardless of genotype (+/+ p = 0.0266, -/- p = 0.0171). No 
significant difference was seen in the loss of SDH activity between genotypes (p = >0.9999) 
shown in figure 27A. Female animals demonstrated a significant loss in SDH activity when 
treated with 3-NP, normalized to saline injection, regardless of genotype (+/+ p = 0.0473, -/- p = 
0.0023). No significant difference was seen in the loss of SDH activity between genotypes (p = 
0.3486) shown in figure 27B.  
In the cortex and hippocampus loss of SDH activity was also observed (figure 28). Male 
animals demonstrated a significant loss in SDH activity when treated with 3-NP, normalized to 
saline injection, regardless of genotype in cortex (+/+ p = 0.0005, -/- p = 0.0016), figure 28A and 
hippocampus (+/+ p = 0.0010, -/- p = 0.0017), figure 28B. No significant difference was seen in 
the loss of SDH activity between genotypes in cortex (p = >0.9999) or in hippocampus (p = 
>0.9999). Female animals demonstrated a significant loss in SDH activity when treated with  
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FIGURE 25: Comparison of the amount and rate of removal of wild-type (+/+) and IL-1R1 null (-
/-) female mice from 3-NP study. Mice receiving 3-NP were removed from injection series if their 
behavioral score exceeded nine (9) or if they lost >20% of their body mass. (A) A Kaplan–Meier 
survival curve depicts the rate at which the mice were removed from study. No genotypic 
differences in rate of removal was determined by Mantel-Cox log-rank test (p = 0.5887). (B) The 
number of IL-1R1+/+ and IL-1R1 −/− mice determined to be moribund are expressed as the percent 
of the total number of mice subjected to the systemic injection paradigm (fraction within bars). 
No genotypic differences were found when compared by Fisher’s exact test (p = >0.9999).  
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3-NP, normalized to saline injection, regardless of genotype in cortex (+/+ p = 0.0245, -/- p = 
0.0026) figure 28C and hippocampus (+/+ p = 0.015, -/- p = 0.0171) figure 28D. No significant 
difference was seen in the loss of SDH activity between genotypes in cortex (p = >0.9999) or in 
hippocampus (p = >0.9999). 
FIGURE 26: Representative images of female wild type and IL-1R1 deficient mice. Female IL-1R1 
null mutant mice (-/-, n = 12) and their wild-type littermates (+/+, n = 6) were injected twice daily 
with 3-NP as described in methods. Photomicrographs depicting striatal injury in IL-1R1+/+ (left) 
and IL-1R1-/- mice (right) at +0.72 to +0.22 from bregma at day 13 following 3-NP exposure.  
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FIGURE 27: Striatal SDH Activity after acute 3-NP injection. IL-1R1 null mutant mice and wildtype 
littermates were injected with 150 mg/kg 3-NP or saline. Two hours after injection, SDH activities 
were measured from crude brain mitochondrial extract as described in methods. Data were 
normalized to each genotype control group (- 3NP) and expressed as mean + SEM. A. Male wild 
type (-3-NP n=5, +3-NP n=4) and IL-1R1 null (-3-NP n=5, +3-NP n=6) demonstrated significant 
between-group differences (*; 3-NP treatment; (+/+ p = 0.0266, -/- p = 0.0171)), but no within-
group (i.e., genotype) differences (p = >0.9999) found by two-way ANOVA followed by 
Bonferonni’s test for multiple comparisons. B. Female wild type (-3-NP n=5, +3-NP n=4) and IL-
1R1 null (-3-NP n=4, +3-NP n=4) demonstrated significant between-group differences (*; 3-NP 
treatment; (+/+ p = 0.0473, -/- p = 0.0023)), but no within-group (i.e., genotype) differences (p = 
0.3486) found by two-way ANOVA followed by Bonferonni’s test for multiple comparisons.  
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FIGURE 28: Cortical and Hippocampal SDH Activity after acute 3-NP injection. IL-1R1 null mutant 
mice and wildtype littermates were injected with 150 mg/kg 3-NP or saline. Two hours after 
injection, SDH activities were measured from crude brain mitochondrial extract as described in 
methods. Data were normalized to each genotype control group (- 3NP) and expressed as mean 
+ SEM. A. Cortex of male wild type (-3-NP n=5, +3-NP n=4) and IL-1R1 null (-3-NP n=5, +3-NP n=6) 
demonstrated significant between-group differences (*; 3-NP treatment; (+/+ p = 0.0005, -/- p = 
0.0016)), but no within-group (i.e., genotype) differences (p = >0.9999) found by two-way ANOVA 
followed by Bonferonni’s test for multiple comparisons. B. Hippocampus of male wild type (-3-
NP n=5, +3-NP n=4) and IL-1R1 null (-3-NP n=5, +3-NP n=6) demonstrated significant between-
group differences (*; 3-NP treatment; (+/+ p = 0.0010, -/- p = 0.0017)), but no within-group (i.e., 
genotype) differences (p = >0.9999) found by two-way ANOVA followed by Bonferonni’s test for 
multiple comparisons. C. Cortex of female wild type (-3-NP n=5, +3-NP n=4) and IL-1R1 null (-3-
NP n=4, +3-NP n=4) demonstrated significant between-group differences (*; 3-NP treatment; 
(+/+ p = 0.0245, -/- p = 0.0026)), but no within-group (i.e., genotype) differences (p = >0.9999) 
found by two-way ANOVA followed by Bonferonni’s test for multiple comparisons. D. 
Hippocampus of female wild type (-3-NP n=4, +3-NP n=4) and IL-1R1 null (-3-NP n=4, +3-NP n=4) 
demonstrated significant between-group differences (*; 3-NP treatment; (+/+ p = 0.015, -/- p = 
0.0171)), but no within-group (i.e., genotype) differences (p = >0.9999) found by two-way ANOVA 
followed by Bonferonni’s test for multiple comparisons. 
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3.4. IL-1R1 Discussion 
In the model of neurodegeneration implemented in this study several observations can 
be made. Male mice lacking IL-1R1 and their wildtype littermates both lose mass in a similar 
manner when treated with 3-NP. The genotype having no observable influence on mass implies 
that the systemic effects of intoxication with a mitochondrial toxin are acting equally on both 
groups of mice. Furthermore, the gross behavioral scoring conducted throughout the dosing 
paradigm indicates no difference in the development of the observable motor deficit between 
the genotypes. When motor deficit is examined in detail, no difference is observed between 
wild type and IL-1R1 null littermates. Further examination of fine behaviour was conducted 
with a rotor-rod test to examine motor control and the inverted grip test to examine grip 
strength. Utilizing the fine behavioral tests a more objective analysis of the development of 
motor deficit could be made. Considering male mice of both genotypes demonstrate no 
statistical difference in loss of mass, increase in gross motor deficit score or decreased latency 
to fall the both tests of fine motor behaviour, it is possible to conclude that male mice with and 
without IL-1R1 respond in the same manner to exposure to 3-NP. However, the histology points 
to a slightly different conclusion. 
The histology of male mouse brain tissue was conducted after the mice either 
completed the study or were sacrificed before completion due to loss of mass greater than 20% 
or incurred behavioral score of 9 or more. Examination of male mouse brain tissue indicated a 
distinct difference between wild type and null animals. Both lesion area as a percentage of the 
striatal area (per section) and lesion volume converted from lesion area measurements were 
considered. It was observed that animals in which IL-1R1 is absent have considerably larger 
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lesion than those in which it is present. It is possible to conclude from these findings that in 
male mice IL-1R1 provides protection from the striatal injury incurred by, the sub-acute 
escalating dosing paradigm administered.  
The histological difference in male mice is distinct, however no behavioral differences 
are evident between the genotypes. If male wild type mouse brain tissue does not contain 
visible lesion but the physical condition of the mice deteriorates in the same manner as the IL-
1R1 null animals, then two possibilities are apparent for this difference. Firstly the observation 
of lesion is dependent on the development of clear cell loss within the striatum. The wild type 
mice may be suffering from cellular damage that is not observable through the staining method 
implemented. Secondly the wildtype mice may not be incurring damage to the striatal tissue 
but are presenting behavioral deficit because of the systemic effects of 3-NP exposure. Further 
experimentation would be needed to determine the reason for difference between male 
histology and behavioral findings.  
To determine if the effect seen in male mice was mediated by the change in IL-1R1 
signalling or a difference in the action of 3-NP between the genotypes an assay of SDH activity 
was conducted. After an acute dose of 3-NP both IL-1R1 null and their wildtype littermates 
demonstrated a similar degree of loss of SDH activity. The assay utilised an assessment of SDH 
activity in crude mitochondrial extract, normalized to total protein content. Using a crude 
extract from tissue samples wherein the mitochondria may be damaged or stressed, could have 
been problematic as if the mitochondria had become enlarged as a result of toxic insult the 
centrifugation used to separate the extract may have erroneously excluded the damaged 
mitochondria isolating only the healthy. However, results from the assays were internally 
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consistent indicating that this was not the case while an acute model is not directly comparable 
to the sub-acute dose. The similar response indicates that 3-NP is not acting differently in either 
genotype.  
In female mice, like in males no statistical difference was seen in the recorded decrease 
in mass or performance in the tests of fine motor behavior. This difference was not statistically 
significant and power analysis of the female gross behaviour score using graphpad statmate 2 
software indicates that at the determined experimental power of the completed experiment an 
n of 8 would be required to detect a significant difference between the two groups. Considering 
the sample size for the wild type genotype was 6 it may be possible that this difference would 
become significant if the sample size was increased. Histological analysis of female mouse brain 
tissue indicated no significant difference between genotypes. 
Findings in this study relate to those of HD through the generation of ROS. 
Administration of 3-NP has been demonstrated to increase ROS in a dose dependent manner 
(Fontaine et al., 2000, Liot et al., 2009) and an increase in ROS is evident in HD (Milakovic and 
Johnson, 2005). In cases of HD the source of injury is the accumulation off HTT protein, and 
disease progression has been associated with increased accumulation (Becher et al., 1998, 
Arrasate and Finkbeiner, 2012). A previous study has demonstrated that loss of IL-1R1 increases 
HTT aggregation in a HD mouse model (Wang et al., 2010). However, in this study 3-NP has 
been used and therefore no HTT aggregation is present and cannot be responsible for the 
observed injury. The protection observed in this study in male, but not female, mice may be 
due to amelioration of ROS damage. Previous work conducted in this laboratory has 
demonstrated that in an in vitro culture of astrocytes, IL-1β pre-treatment is protective against 
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an organic peroxide via a GSH dependent mechanism and signalling through IL-1R1 is required 
for this protection to be evident (He et al., 2015). Further, IL-1β has been demonstrated to 
increase the expression of xCT a component of system xc-, an antiporter which imports the rate 
limiting component required for GSH synthesis (Shi et al., 2016, Fogal et al., 2007, Jackman et 
al., 2010). This study demonstrates when a chemical known to increase ROS is administered, 
the presence of IL-1R1 is protective. Such findings are consistent with previous work indicating 
IL-1β can result in in increased GSH production in vitro. More research is needed to 
demonstrate a direct association in the model implemented in this study.   
The protection observed in males is not present in the female mice tested. This study 
presents no evidence to explain this difference. If the protection is associated with the 
upregulation of xCT there is some evidence in published literature to suggest an involvement of 
estrogen in xCT regulation which indicating a possible reason for the difference. In studies 
employing breast cancer cells, the estrogen receptor has been shown to be involved in xCT 
expression with an estrogen response element being computationally identified in the xCT 
promoter region (Linher-Melville et al., 2015). To further tie estrogen to xCT, Pit-1 sites, which 
have been long associated with estrogen signalling, have been identified in the non-coding 5’ 
region of xCT (Nowakowski and Maurer, 1994, Linher-Melville et al., 2015). What effect, if any, 
estrogen has on xCT regulation is not yet fully understood, but if estrogen were upregulating 
xCT the action of IL-1R1 signalling may not be able to further upregulate xCT. If the upregulation 
of xCT is able to redress the redox imbalance created by the increased generation of ROS an 
inability to increase xCT expression would result in females being unable to compensate for 
ROS generated by 3-NP dosing. If this were true a higher basal expression of xCT in females may 
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explain why in previous studies females where resistant to 3-NP dosing. Although, wild type 
females in this study did not display such innate resistance.   
The limitations of this study suggest caution in drawing sweeping conclusions. The use 
of only one stain to examine histology resulted in only one gross assessment of injury. Including 
a specific neuronal stain would have allowed an accurate quantification of neuronal cell loss in 
addition to the assessment of lesion size. Such an extension of this study would have allowed a 
more detailed analysis of histological sections which did not show lesion damage. Further, in 
this analysis had a mitotracker stain or the examination of other markers of oxidative 
phosphorylation been used an assessment of mitochondrial function as well as oxidant 
mediated cell death could have been made. The purpose of this study was to examine the 
effect of 3-NP on mice with and without IL-1R1. The most evident limitation of this study is the 
lack of analysis of the mechanism behind the effect. With no evidence directly examining the 
mechanism behind the observed protection in males, it is not possible to make any direct 
assertions to what mediates the protective effect of IL-1R1 signalling in males in this study. 
Possibilities for further study into the effect seen in this thesis will be discussed in detail in 
chapter four. 
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4. CHAPTER FOUR 
4.1. Does IL-1β signalling have a protective effect? 
IL-1β signalling is heavily dependent on environmental conditions. IL-1 signalling has 
been shown to be detrimental in a number of models, particularly those modelling ischemic 
stroke (Fogal et al., 2007, Yang et al., 1998). Free radical accumulation and energy deprivation is 
associated with stroke but also with the administration of 3-NP. The findings of this study, that 
IL-1β signalling in male (but not female) mice protects against 3-NP induced striatal injury, 
indicates that the pleiotropic effects of IL-1β signalling, influence physiological outcomes. The 
findings of this study are supported by studies which demonstrated a protective effect of IL-1β 
against oxidative stress in astrocytes (He et al., 2015) and astrocyte neuron co-culture 
(Choudhury, unpublished). Support from previous studies and the demonstrated reproducibility 
indicate the result seen in this study represents a real effect that needs further study to 
elucidate the mechanism underlying the protection seen in this model.  
 
4.2. Future Directions 
To definitively rule out any genotypic difference in the ability of 3-NP to inhibit SDH, the 
SDH assay could be next performed at set time points throughout the sub-acute dosing 
paradigm. The data shows loss of SDH activity in the cortex and in the hippocampus. By 
conducting the experiment during the sub-acute paradigm, it would be possible demonstrate 
the rate of SDH inhibition and show the effect on other brain regions when receiving multiple 
sub-acute doses. To address the issue limited histological analysis, IL-1R1 animals and wild type 
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littermates should be utilized to label different types of cell by immunofluorescence. To 
examine comparable sections throughout the lesioned area and determining the effects on 
different cell types. Such an investigation will provide insight into the observed cell loss and 
which cell type if any is more severely affected. By labelling different cell types it would be 
possible to observe the differing response primarily if neurons experience more cell loss 
depending on genotype or if astrocytes are effected to a different extent. Examining microglia 
would also enable a measure of microglial activation. Conducting additional cohorts in which 
animals are removed for immunofluorescent analysis at set time points over the injection time 
course would demonstrate the development of cell loss in regards to cell type. By examining 
the development it will be possible to see which cell types are affected first. 
To determine if the protection observed is due to the upregulation of xCT, a sub cohort 
of the animals should be utilized to examine changes in xCT mRNA expression. Such an 
experiment could be achieved by dividing the hemispheres of the animals used for a time 
course of SDH activity and extracting RNA from the hemisphere not used for mitochondrial 
extraction. IL-1β enhances the synthesis and export of GSH (He et al., 2015). Although, this has 
been demonstrated in vitro it would be beneficial to conduct this experiment in vivo to 
elucidate if the same effect is occurring in the model utilized in this study which would provide 
in vivo support for in vitro findings. To determine whether our findings are mechanistically 
linked to system xc-, an in vitro approach could be taken.  
In a separate cohort of animals, biological markers of oxidative stress would be 
measured and compared between wild-type and IL-1R1 null mice. At the cessation of the dosing 
protocol, the ratio of reduced and oxidized glutathione (GSH/GSSG) can be quantified in 
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cerebro-spinal fluid and in brain tissue, to assess the extra and intracellular activity of 
glutathione respectively. The quantity of 8-OHG, an oxidative stress marker of RNA damage, 
and 4-HNE, a marker of lipid peroxidation can be measured via ELISA. Examining oxidative 
stress markers in different regions of the brain will enable a determination of the type of 
damage occurring during the injection paradigm. 
Finally, an in vitro approach that represents the in vivo situation could be used to 
elucidate mechanism. Organotypic slice cultures (400µm coronal sections), derived from P7 
pups from wild-type or sut/sut littermates, could be treated with vehicle or IL-1β, after which 3-
NP could be added. The extent of SDH inhibition, striatal cell viability, and oxidative stress, 
could be measured for comparison. Additionally, cell viability of the cultures could be 
quantified via measurement of lactate dehydrogenase released into the cell culture medium. 
The presence of oxidative stress markers could be quantified and compared. ROS could be 
measured via dihydroethidium fluorescence imaging.  
Investigating the cell types effected in the dosing paradigm would better characterize 
the effects of the experimental model. While important it is necessary to associate the 
observed protection with an underlying mechanism. It is hypothesised in this thesis that the 
underlying cause is an upregulation of xCT resulting in the increased generation of GSH. The 
examination of secreted GSH shuttled into the CSF and the intracellular GSH present in tissue 
samples would demonstrate if the more GSH is produced and expressed following 3-NP 
treatment. The assessment of markers of oxidative stress will demonstrate that the 
administration of 3-NP is resulting in cellular damage from ROS. In measurements of both GSH 
and oxidative stress markers the use of IL-1R1+/+ and IL-1R1-/- littermates should demonstrate 
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greater oxidative stress markers in IL-1R1 null animals but greater GSH in wild type. Finally, to 
tie IL-1R1 activity to xCT in vivo the use of sut/sut animals could replicate IL-1R1 null findings.      
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Appendix A 
Pilot Study Sham Mass 
A study has demonstrated that male and female C57Bl/6J mice have statistically 
significant difference in body mass (Reed et al., 2007). The average mass of males was 
significantly different in comparison to day one after day five indicating significant loss of mass. 
Loss of mass in males could indicate a differing response to stress caused from repeated 
injection.  
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FIGURE S1: Comparison of saline-mediated mass loss in C57Bl/6J mice. Mass of male (n 
= 3) and female (n = 3) mice, were assessed and recorded just prior to each sham 3-NP 
injection.  Mass was plotted as mean ± SEM. There was a significant time-effect after day 
five at p = <0.0004) for male mice only. There was no statistically significant difference 
between sexes (p = 0.1098), as determined by repeated measures two-way ANOVA with 
Sidak’s multiple comparisons. 
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Pilot Study Sham Behavioral Score
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FIGURE S2: Comparison of saline-mediated motor deficit in C57Bl/6J mice. Gross motor 
behavior of male mice (n = 5) and female (n = 5) were assessed and recorded just prior to each 
3-NP injection.  The average score for the day was plotted as mean ± SEM. A significant difference 
over time was seen in both sexes (p = <0.0001). There was a statistically significant difference 
between sex at day 8 only (p = <0.0001), as determined by two-way ANOVA, with Sidak’s multiple 
comparisons, after [Y = log (Y + 1)] transformation. 
 
Animal score was incurred by both sexes in the later stages of injection, driven by the 
fact that mice became less active, although mice appeared to be in good health and 
demonstrated no sign of motor deficit. Score never exceeded one and demonstrated no sign of 
distress throughout the protocol. 
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Pilot Study Sham Representative Image 
 
FIGURE S3: Representative images of male and female saline injected and Naïve mice. 
Photomicrographs depicting thionin stained coronal sections from saline (left) and naïve mice 
(right) at +1.02 to +0.22 from bregma at day 13 following saline injection as detailed in methods 
for 3-NP injection, or between from naïve animal sacrificed between the age of 16-18 weeks. 
 
No difference was seen between male or female animals treated with saline or male and 
female naïve animals. No lesion or abnormality was observed during any stage of histological 
processing or analysis in any of the four groups detailed in figure S3. 
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IL-1R1 Sham Mass 
 
Saline treated animals from IL-1R1 cohorts replicate findings from pilot study saline 
treated animals. It is unclear what causes the males but not the females to lose mass during 
sham injection. The number of female wild type animals which received sham treatment was 
decreased to one because on secondary post mortem genotyping some animals were revealed 
to be heterozygous at the IL-1R1 allele.  
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FIGURE S4: Comparison of saline-mediated mass loss in male and female wild type and IL-
1R1 null mice. Mass of IL-1R1 null (n = 6) and wild type littermates (n = 7) mice, were assessed 
and recorded just prior to each saline 3-NP injection.  Mass was plotted as mean ± SEM. 
Females demonstrated no significant difference between genotype or over time (genotype p 
= 0.3843, time p = 0.9689,). Males demonstrated no difference by genotype but a significant 
difference over time (genotype p = >0.9999, time p = 0.0045) as determined by two-way 
ANOVA. 
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IL-1R1 Sham Behavioral Score 
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FIGURE S5: Comparison of saline-mediated motor deficit in C57Bl/6J mice. Gross motor 
behavior of male mice (n = 5) and female (n = 5) were assessed and recorded just prior to each 
3-NP injection.  The average score for the day was plotted as mean ± SEM. A significant difference 
over time was seen in both sexes (p = <0.0001). There was a statistically significant difference 
between groups infrequently after day 8 (p = <0.0245 at all differing comparisons), as determined 
by two-way ANOVA, with Sidak’s multiple comparisons, after [Y = log (Y + 1)] transformation. 
 
In instances when saline animals received a behavioral score, this was due to occasional 
intermittent clasping possibly because of irritation at the injection site. No animal appeared in 
distress throughout saline injection with no gross changes in behaviour was observed 
regardless of sex or genotype.  
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IL-1R1 Study Sham Representative Image 
 
FIGURE S6: Representative images of male and female sham injected of both wild type and IL-
1R1 null genotypes. Photomicrographs depicting thionin stained coronal sections from male (left) 
and female mice (right) at +1.02 to +0.22 from bregma at day 13 following sham injection as 
detailed in methods for 3-NP injection. 
 
 
No difference was seen between male or female animals treated with saline of either 
genotype. No lesion or abnormality was observed during any stage of histological processing or 
analysis in any of the four groups as representatively demonstrated in figure S6. 
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FIGURE S7: Representative images of wild type and IL-1R1 null naïve animals. Photomicrographs 
depicting thionin stained coronal sections from male wild type (left) and IL-1R1 null mice (right) 
at +1.02 to +0.22 from mice sacrificed between 16 – 18 weeks of age. 
 
 
No difference was seen between male, female, saline or naïve animals regardless of 
genotype. No visible lesion was present in any case and no observable abnormalities was 
noticed between any treated groups.  
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FIGURE S8: Comparison of total mass lost between IL-1R1 null and their wild type littermates 
in male mice exposed to 3-NP or saline dosing. Mice received twice daily injection of 3-NP (+3-
NP) or saline injection (–3-NP) as detailed in methods section. Total mass lost is calculated by 
subtracting the final animal mass from the starting mass. Group comparisons made by 2x2 two 
way ANOVA. A significant overall difference is seen between 3-NP treated and saline-treated 
animals (p = 0.0005) and between IL-1R1 null saline and 3-NP-treatment (p = 0.002) but not in 
wild type (p = 0.1417). There is no significant difference between wild type and IL-1R1 3-NP 
treated groups (p = 0.23) 
 
Comparing the total mass lost indicates a significant difference between treatments in 
the IL-1R1 null genotype only. A far greater spread in lost mass is seen in wild type animals 
treated with 3-NP, however the mean value does not vary greatly from that seen in saline 
treated.  
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Summary of saline treated animal and naïve findings 
Male mice appear to lose mass when injected with saline, whereas females do not. As a 
previous study has indicated male and female C57Bl/6J have the same body fat composition 
(Reed et al., 2007), therefore the loss of mass is less likely to be attributed to excess fat loss in 
males. The wild type male animals depict a large variation in the amount of mass lost. There 
remains a clear difference in observable motor deficit and histology compared to saline-treated 
animals as expected.  
Saline vehicle treatment had no observable effect on the animals. Histology demonstrates no 
visual difference between saline vehicle-treated and naïve animals. Sex or genotype had no 
effect on the presence of lesion in saline-treated and naïve animals. 
C57Bl/6 Striatal Volume Assessment 
Striatal volume calculations 
made in this work demonstrated an 
equivalent striatal volume of 12mm3 
(see chapters two and three). 
Measurement where made from 
sections taken within the collected 
region and converted to a volume 
using Cavailari’s principle. While 
striatal volume was reasonably 
consistent throughout this study, a 
FIGURE S9: Cartoon indicating the region of striatum 
collected for analysis during this project. Horizontal line 
denotes length of striatum throughout mouse brain 
relative to bregma as indicated from Allen Brain Atlas 
data. Red line marked by ‘B’ denotes bregma. The region 
between the two vertical lines was collected in 40µm 
cryosections as detailed in methodology 
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difference is seen between this study, and published whole striatal measurements. Three 
studies utilizing C57Bl/6 mice reported a total striatal volume of 23mm [see (Harms et al., 2012, 
Rosen et al., 2009, Rosen and Williams, 2001)]. The determined volume in this work represents 
half of that reported in literature. Only a short region of the striatum was collected for this 
study. The striatum spans 4.26mm in length but collections were only made over a 1.4mm span. 
When the striatum is visualised in a 2D format by charting striatal span and striatal width at 
multiple points the collections were made in the largest region of the striatum. It is plausible to 
assume the volume measurements made in this work represents half of the total striatum and 
is consistent with the reported measurements.    
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